Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	disaccharide binding	LGALS9C LGALS9B LGALS9	8.96e-05	7	278	3	GO:0048030
GeneOntologyMolecularFunction	ATP-dependent activity	ABCA2 MYO9A PSMC2 KATNAL1 SRCAP ABCA7 DDX3X HFM1 KIF22 CECR2 DNAH2 NLRP1 DDX56 MSH2 DNAH1 DDX3Y MYO15A ATP1B2 YME1L1 ATP5F1A DNAH11	1.51e-04	614	278	21	GO:0140657
GeneOntologyMolecularFunction	galactoside binding	LGALS9C LGALS9B LGALS9	2.11e-04	9	278	3	GO:0016936
GeneOntologyBiologicalProcess	negative regulation of natural killer cell degranulation	LGALS9C LGALS9B LGALS9	9.18e-06	4	274	3	GO:0043322
Domain	FN3_dom	BOC MYLK OBSCN TRIL PTPRD PTPRS FNDC9 FLNC IL31RA COL12A1 DSCAM IGSF9B MYBPC2	1.26e-05	209	272	13	IPR003961
Domain	SPOC_C	RBM15B DIDO1 PHF3	5.91e-05	6	272	3	IPR012921
Domain	SPOC	RBM15B DIDO1 PHF3	5.91e-05	6	272	3	PF07744
Domain	FN3	BOC MYLK OBSCN PTPRD PTPRS FLNC IL31RA COL12A1 DSCAM IGSF9B MYBPC2	8.79e-05	185	272	11	SM00060
Domain	Ig_I-set	BOC MYLK OBSCN IGSF10 HEPACAM PTPRD PTPRS ALPK3 DSCAM IGSF9B MYBPC2	1.11e-04	190	272	11	IPR013098
Domain	I-set	BOC MYLK OBSCN IGSF10 HEPACAM PTPRD PTPRS ALPK3 DSCAM IGSF9B MYBPC2	1.11e-04	190	272	11	PF07679
Domain	fn3	BOC MYLK OBSCN PTPRD PTPRS IL31RA COL12A1 DSCAM IGSF9B MYBPC2	1.35e-04	162	272	10	PF00041
Domain	FN3	BOC MYLK OBSCN PTPRD PTPRS FNDC9 IL31RA COL12A1 DSCAM IGSF9B MYBPC2	1.68e-04	199	272	11	PS50853
Domain	IGc2	BOC MYLK OBSCN IGSF10 HEPACAM PTPRD PTPRS ALPK3 DSCAM IGSF9B BCAM MYBPC2	1.80e-04	235	272	12	SM00408
Domain	Ig_sub2	BOC MYLK OBSCN IGSF10 HEPACAM PTPRD PTPRS ALPK3 DSCAM IGSF9B BCAM MYBPC2	1.80e-04	235	272	12	IPR003598
Pubmed	Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.	GPHN VPS16 TRIP11 DDX3X ADD2 SPICE1 CAMSAP1 DNMBP MAP4K4 MIA3 CDC42BPA MSH2 NCKAP5L NBAS LMO7 NCOA7 CEP131 CSPP1	2.86e-12	251	280	18	29778605
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	GPHN SF3B4 RIMKLA MYO9A RASSF2 TRIP11 MEF2D DDX3X SPICE1 NF1 RABGEF1 TSC22D4 CAMSAP1 DNMBP MAP4K4 CDC42BPA CARMIL1 BRSK2 NCKAP5L MADD PPP1CA NHSL1 SLC16A1 LMO7 CSNK1D PHF3 NCOA7 CEP131 CSPP1 PCDH7 USP6NL	4.35e-12	861	280	31	36931259
Pubmed	MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.	GTPBP4 ZHX3 KMT2B ZNF318 ACTL6A GNL2 MGA SF3B2 FOXM1 GINS3 DIDO1 MSH2 GMNN AAR2 PPP1CC GTF2F1 TSR1 PDCD11	4.00e-10	339	280	18	30415952
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	SF3B4 PSMC2 PPP1R13L ADD2 SPICE1 ZFYVE9 PTPRD PTPRS MKI67 GNL2 UXT KIF22 MIA3 CDC42BPA MSH2 NCKAP5L CDCA8 MADD PPP1CA PPP1CC NHSL1 GTF2F1 TSR1 YLPM1 CEP131 MAPK11 CDC25A CSPP1 YME1L1 PCDH7 ATP5F1A	5.77e-10	1049	280	31	27880917
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	FILIP1 ZHX3 KMT2B SF3A1 ZNF318 MECP2 MEF2D SPICE1 NF1 MKI67 RBM15B DNMBP MAP4K4 SF3B2 FOXM1 SGTA CARMIL1 DIDO1 ECPAS HEXIM2 KANSL1 LMO7 PHF3 YLPM1 PCDH7	5.15e-09	774	280	25	15302935
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	GTPBP4 SF3B4 AUH SF3A1 APTX IREB2 MECP2 LARP4B NFX1 MKI67 GNL2 RBM15B PKM NKTR SF3B2 GPI CDC42BPA NOP16 DIDO1 DDX56 ANKZF1 CTSA HEXIM2 PPP1CC TSR1 LMO7 CSNK1D PHF3 YLPM1 PDCD11 DDX3Y CEP131 RPP25L ATP5F1A	6.98e-09	1371	280	34	36244648
Pubmed	Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.	EPPK1 LZTS3 MYO9A VPS13C VPS16 ADGRV1 GALNT16 ITIH1 ADD2 NF1 CASKIN1 DLG2 SYT5 ALG2 PPP1CA LLGL1 CSNK1D CDH2	1.66e-08	430	280	18	32581705
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	GTPBP4 SF3B4 SF3A1 ACTL6A SRCAP MECP2 DDX3X ADD2 GNL2 RBM15B PKM MAP4K4 SF3B2 DNMT3B NPAS2 MTIF3 FLNC CDC42BPA CECR2 DIDO1 DDX56 PPP1CA PPP1CC LLGL1 SLC16A1 TSR1 YLPM1 DDX3Y MPHOSPH8	1.85e-08	1082	280	29	38697112
Pubmed	H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.	GTPBP4 SF3B4 KMT2B SF3A1 APTX ZNF318 ACTL6A SRCAP MECP2 DDX3X ACTL8 MKI67 RBM15B NKTR MGA SF3B2 KIF22 MED6 ACTR8 NOP16 DIDO1 DDX56 MSH2 PPP1CA PPP1CC KANSL1 LMO7 PHF3 YLPM1 PDCD11 MPHOSPH8 ATP5F1A	2.15e-08	1294	280	32	30804502
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	GPHN GTPBP4 GPRASP1 LZTS3 ZNF318 TRIP11 ITIH1 DDX3X SPICE1 NF1 PTPRD PTPRS CASKIN1 DLG2 RABGEF1 CAMSAP1 MGA MAP4K4 MIA3 DSCAM DIDO1 GRIN2D PPP1CA PPP1CC YLPM1 CEP131 CDH2	2.37e-08	963	280	27	28671696
Pubmed	FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.	BDP1 ZHX3 DCHS2 ACACB OBSCN ACTL6A NEB DYSF RYR3 COPS8 GNL2 MAP4K4 CARMIL1 ECPAS PPP1CA LMO7 LRBA CSPP1 HYDIN	2.80e-08	497	280	19	36774506
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	ABCA2 EPPK1 KMT2B OBSCN SRCAP DYSF ABCA7 SLC38A10 PTPRS CASKIN1 OSBPL5 PKD1 NFX1 CAMSAP1 DNMBP FLNC CDC42BPA DDX56 ST3GAL1 GRIN2D MADD HIVEP3 NHSL1 KANSL1 ANKRD34A PDCD11 CEP131 BCAM LRBA	2.92e-08	1105	280	29	35748872
Pubmed	Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex.	EPPK1 RASSF2 PSMC2 ACTL6A MIA2 PKM MMS19 CIAO2A MAP4K4 KIF22 BRWD1 GPI MIA3 MSH2 TSR1 CEP131 RPP25L	3.24e-08	399	280	17	37536630
Pubmed	Nuclear actin interactome analysis links actin to KAT14 histone acetyl transferase and mRNA splicing.	GPHN GTPBP4 ZHX3 SF3B4 KMT2B SF3A1 ZNF318 ACTL6A SRCAP CRACD MKI67 SF3B2 MSH2 PPP1CC GTF2F1 LMO7 PHF3 YLPM1 ATP5F1A	3.72e-08	506	280	19	30890647
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	GPHN GTPBP4 ZHX3 ACACB SF3A1 PSMC2 ZNF318 SRCAP TRIP11 DDX3X CRACD MKI67 GNL2 PKM PRMT7 CAMSAP1 SF3B2 UBFD1 GPI CARMIL1 DIDO1 SPAG7 YLPM1 NCOA7 LRBA ATP5F1A	5.02e-08	934	280	26	33916271
Pubmed	Identifying biological pathways that underlie primordial short stature using network analysis.	GTPBP4 EPPK1 SF3A1 ZNF318 SRCAP DDX3X NF1 AARS2 MKI67 GNL2 PKM HEATR5B MGA MAP4K4 SF3B2 KIF22 GPI FLNC DDX56 MSH2 CDCA8 PPP1CA LMO7 YLPM1 PDCD11 CEP131 ATP5F1A	8.21e-08	1024	280	27	24711643
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	GTPBP4 EPPK1 SF3A1 PSMC2 ZNF318 LARP4B NF1 MKI67 GNL2 SF3B2 FLNC DIDO1 DDX56 MSH2 ECPAS PPP1CA PPP1CC TSR1 PHF3 YLPM1 PDCD11	9.76e-08	653	280	21	22586326
Pubmed	A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins.	SF3B4 OPN3 VPS13C APTX IREB2 ACTL6A ADD2 SLC38A10 MICB FGD1 MMS19 CIAO2A MAP4K4 CDC42BPA ALG2 MADD LLGL1 NCOA7 BCAM LRBA CDH2 USP6NL	1.13e-07	719	280	22	35337019
Pubmed	Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity.	MYLK RASSF2 SF3A1 MLKL NF1 AGO4 NRK SCAPER NKTR POGLUT2 MAP4K4 ZDHHC18 IL31RA CDC42BPA BRSK2 CDCA8 GMNN PRX HEXIM2 PPP1CA PPP1CC CSNK1D PARVA IGSF9B MAPK11	1.18e-07	910	280	25	36736316
Pubmed	Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.	GTPBP4 SF3B4 EPPK1 SF3A1 ACTL6A PPP1R13L TRIM29 MECP2 DDX3X LARP4B MKI67 GNL2 RBM15B PKM GAPDHS SF3B2 NOP16 DIDO1 DDX56 MSH2 PPP1CA AAR2 PPP1CC SLC16A1 TSR1 LMO7 CSNK1D PHF3 PDCD11 ATP5F1A	1.32e-07	1257	280	30	36526897
Pubmed	A human skeletal muscle interactome centered on proteins involved in muscular dystrophies: LGMD interactome.	BOC SETD6 OBSCN NEB DYSF TRIP11 LARP4B PKM RABGEF1 MGA FLNC COL12A1 VWF CDC42BPA LAMA2 PPP1CC PLCE1 MYBPC2	1.46e-07	497	280	18	23414517
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	GPRASP1 DCHS2 ABCA2 SF3B4 TRIP11 FRMD4B DDX3X RYR3 PTPRD MIA2 PKD1 PKM DLG2 MAP4K4 SF3B2 NR1D2 BRWD1 ACTR8 VWF DSCAM SGTA SLC4A3 MADD LMO7 YLPM1 LRBA PBX2 PBX3 YME1L1 ATP5F1A	2.10e-07	1285	280	30	35914814
Pubmed	Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim‑3 and galectin‑9, in cervical cancer.	LGALS9C LGALS9B FOXM1 LGALS9	2.81e-07	8	280	4	31661141
Pubmed	Defining the membrane proteome of NK cells.	GTPBP4 ABCA2 PSMC2 LARP4B NF1 AGO4 MIA2 OSBPL5 MKI67 GNL2 MMS19 HEATR5B GPI MED6 MIA3 DDX56 ST3GAL1 MSH2 ECPAS ANKZF1 CTSA ALG2 NBAS SLC16A1 DDX3Y LRBA YME1L1 ATP5F1A	3.24e-07	1168	280	28	19946888
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	GTPBP4 SF3B4 SF3A1 MATN2 PSMC2 ACTL6A MEF2D DDX3X SPICE1 MKI67 PKM MGA SF3B2 KIF22 GPI MED6 CDC42BPA NOP16 MSH2 HEXIM2 PPP1CA PPP1CC DNAH1 TSR1 LMO7 CSNK1D PHF3 DDX3Y ATP5F1A	3.68e-07	1247	280	29	27684187
Pubmed	Functional proteomics mapping of a human signaling pathway.	KMT2B PSMC2 PPP1R13L TRIM29 DDX3X SOX7 ZFYVE9 PKD1 RABGEF1 DIAPH3 CAMSAP1 MGA FLNC VWF PPP1CA EPG5 PPP1CC KANSL1 YLPM1	4.06e-07	591	280	19	15231748
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	MEF2D AARS2 OSBPL5 SCAPER MKI67 WHRN FAM220A DNAH2 ANKZF1 PHF3 ANKRD34A DNAH11	4.85e-07	233	280	12	37704626
Pubmed	Galectin-9 regulates follicular helper T cells to inhibit humoral autoimmunity-induced pulmonary fibrosis.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	33316546
Pubmed	Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	28704475
Pubmed	Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23836896
Pubmed	Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	7890611
Pubmed	Galectin-9 Is a Novel Regulator of Epithelial Restitution.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	32380082
Pubmed	Galectin-9-mediated protection from allo-specific T cells as a mechanism of immune privilege of corneal allografts.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23667648
Pubmed	Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	28877989
Pubmed	Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	19800850
Pubmed	Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	37105392
Pubmed	Galectin-9/Tim-3 pathway mediates dopaminergic neurodegeneration in MPTP-induced mouse model of Parkinson's disease.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	36479526
Pubmed	Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23242525
Pubmed	Galectin-9 in allergic airway inflammation and hyper-responsiveness in mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	19851072
Pubmed	The Role of Galectin-9 as Mediator of Atopic Dermatitis: Effect on Keratinocytes.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	33923930
Pubmed	Intracellular Galectin-9 Enhances Proximal TCR Signaling and Potentiates Autoimmune Diseases.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	31969388
Pubmed	Galectin-9 functionally impairs natural killer cells in humans and mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23408620
Pubmed	Galectin-9 Is Critical for Mucosal Adaptive Immunity through the T Helper 17-IgA Axis.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	29458010
Pubmed	Cooperative Interactions of Oligosaccharide and Peptide Moieties of a Glycopeptide Derived from IgE with Galectin-9.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	26582205
Pubmed	Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	9153289
Pubmed	Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23144904
Pubmed	The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	21146220
Pubmed	Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	16990264
Pubmed	Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	18005988
Pubmed	Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	23585851
Pubmed	Alarmin function of galectin-9 in murine respiratory tularemia.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	25898318
Pubmed	Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	18282810
Pubmed	The protective function of galectin-9 in liver ischemia and reperfusion injury in mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	25931247
Pubmed	Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	17560833
Pubmed	Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	19776007
Pubmed	Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	9038233
Pubmed	Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	22341088
Pubmed	The effect of Toxoplasma gondii infection on galectin-9 expression in decidual macrophages contributing to dysfunction of decidual NK cells during pregnancy.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	38987795
Pubmed	Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	35241678
Pubmed	Possible regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung inflammation in mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	22627368
Pubmed	Galectin-9 is required for endometrial regenerative cells to induce long-term cardiac allograft survival in mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	33153471
Pubmed	T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	22052881
Pubmed	Galectin-9 supports primary T cell transendothelial migration in a glycan and integrin dependent manner.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	35643073
Pubmed	Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	18974023
Pubmed	Impaired Gal-9 Dysregulates the PBMC-Induced Th1/Th2 Imbalance in Abortion-Prone Matings.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	29651447
Pubmed	Regulation of M1‑type and M2‑type macrophage polarization in RAW264.7 cells by Galectin‑9.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	28990062
Pubmed	Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	18579572
Pubmed	Galectin-9 ameliorates anti-GBM glomerulonephritis by inhibiting Th1 and Th17 immune responses in mice.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	24477688
Pubmed	A unique role for galectin-9 in angiogenesis and inflammatory arthritis.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	29433546
Pubmed	Amelioration of bleomycin-induced pulmonary fibrosis via TGF-β-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	31937306
Pubmed	Intestinal epithelial cells express galectin-9 in patients with food allergy that plays a critical role in sustaining allergic status in mouse intestine.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	21426359
Pubmed	Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	24083426
Pubmed	Galectin-9 in synergy with NF-κB inhibition restores immune regulatory capability in dendritic cells of subjects with food allergy.	LGALS9C LGALS9B LGALS9	5.16e-07	3	280	3	37279535
Pubmed	Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.	GTPBP4 SF3B4 MYO9A ACTL6A DDX3X LARP4B GNL2 PKM DDX56 MSH2 PPP1CC LLGL1 SLC16A1 TSR1 PDCD11 YME1L1 ATP5F1A	5.29e-07	486	280	17	30940648
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	GPHN SF3A1 ACTL6A TRIM29 MECP2 MEF2D CRACD AARS2 PKM MMS19 CAMSAP1 MGA SF3B2 KIF22 FOXM1 FLNC REL ECPAS HEXIM2 KANSL1 PBX2 CDC25A PBX3	5.77e-07	857	280	23	25609649
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	GPHN KMT2B PSMC2 ZNF318 ACTL6A SRCAP PKM DIAPH3 MGA MAP4K4 DIDO1 PPP1CA SLC16A1 LMO7 PHF3 YLPM1 PDCD11 LRBA	6.22e-07	549	280	18	38280479
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	GPHN IL16 LZTS3 MYO9A TRIP11 MECP2 ADD2 CRACD NF1 PTPRS CASKIN1 SCAPER PKM DLG2 TSC22D4 GPI FLNC VWF CARMIL1 BRSK2 ALG2 MADD PPP1CA PPP1CC NHSL1 LMO7 CSNK1D DDX3Y CDH2 ATP5F1A DNAH11	6.49e-07	1431	280	31	37142655
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	GTPBP4 ZNF318 ACTL6A SRCAP DDX3X LARP4B NF1 MKI67 GNL2 MMS19 NKTR CAMSAP1 MIA3 DDX56 PHF3 YLPM1	6.91e-07	440	280	16	34244565
Pubmed	R2TP/Prefoldin-like component RUVBL1/RUVBL2 directly interacts with ZNHIT2 to regulate assembly of U5 small nuclear ribonucleoprotein.	SF3A1 ACTL6A SRCAP GNL2 UXT SF3B2 ACTR8 CDC42BPA PPP1CA AAR2 PPP1CC TSR1 ATP5F1A	1.14e-06	300	280	13	28561026
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	MYO9A SF3A1 PSMC2 DDX3X ADD2 SPICE1 PKM DIAPH3 CAMSAP1 MAP4K4 SF3B2 CDC42BPA CARMIL1 ECPAS LLGL1 SLC16A1 LRBA PCDH7 USP6NL ATP5F1A	1.49e-06	708	280	20	39231216
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	GIPC2 KMT2B APTX ZNF318 NDUFA7 MECP2 CRACD LARP4B SLC25A40 NFX1 GNL2 RBM15B HEATR5B DNMBP KIF22 MED6 CDC42BPA NOP16 DIDO1 DDX56 ANKZF1 PPP1CC GTF2F1 TSR1 PHF3 PDCD11 MPHOSPH8 CEP131 YME1L1 USP6NL ATP5F1A	1.66e-06	1497	280	31	31527615
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	ABCA2 VPS13C ADGRV1 FRMD4B AGO4 CASKIN1 OSBPL5 DNMBP MAP4K4 CDC42BPA CECR2 DIDO1 ECPAS TSR1 LMO7 PDCD11 USP6NL	1.68e-06	529	280	17	14621295
Pubmed	A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex.	GPHN ZHX3 MECP2 MEF2D TSC22D4 PRMT7 CAMSAP1 DIDO1 MSH2 ECPAS CDCA8 LLGL1 PHF3 DDX3Y MPHOSPH8 CEP131	1.72e-06	472	280	16	38943005
Pubmed	Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression.	LGALS9C LGALS9B MATN2 ITIH1 BMP1 FBLN5 COL12A1 VWF LAMA2 LGALS9	1.73e-06	175	280	10	28071719
Pubmed	Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	22677125
Pubmed	Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	19234217
Pubmed	Tim-3/Galectin-9 signaling pathway is involved in the cytokine changes in mice with alveolar echinococcosis.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	35715604
Pubmed	Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	19017954
Pubmed	Galectin-9: A novel promoter of atherosclerosis progression.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	36459823
Pubmed	Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	29611821
Pubmed	Lgals9 deficiency ameliorates obesity by modulating redox state of PRDX2.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	33727589
Pubmed	[Expression and significance of galectin-3 and galectin-9 in mice nasal mucosa with allergic rhinitis].	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	18826117
Pubmed	[Expression of Galectin-9 and Tim-3 in lungs of mice with asthma].	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	21575348
Pubmed	Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	18346632
Pubmed	Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	19670381
Pubmed	Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	25450716
Pubmed	Galectin-9 regulates the threshold of B cell activation and autoimmunity.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	34369876
Pubmed	Targeting the CD146/Galectin-9 axis protects the integrity of the blood-brain barrier in experimental cerebral malaria.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	33203936
Pubmed	Galectin-9 Targets NLRP3 for Autophagic Degradation to Limit Inflammation.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	33963043
Pubmed	Lipopolysaccharide mediates time-dependent macrophage M1/M2 polarization through the Tim-3/Galectin-9 signalling pathway.	LGALS9C LGALS9B LGALS9	2.05e-06	4	280	3	30763585
Interaction	YWHAH interactions	ABCA2 EPPK1 RIMKLA MYO9A RASSF2 PSMC2 TRIP11 MEF2D DDX3X NF1 AARS2 OSBPL5 RBM15B RABGEF1 NKTR TSC22D4 CAMSAP1 DNMBP MAP4K4 UBFD1 CDC42BPA CARMIL1 NCKAP5L MADD PPP1CA NHSL1 SLC16A1 LMO7 CSNK1D PHF3 NCOA7 CEP131 LRBA CDC25A CSPP1 USP6NL	9.15e-07	1102	273	36	int:YWHAH
Interaction	H3C1 interactions	GTPBP4 KMT2B PSMC2 SRCAP NEB TRIM29 MECP2 MKI67 GNL2 PRMT7 CAMSAP1 MGA SF3B2 KIF22 DNMT3B SGTA DNAH2 LAMA2 DIDO1 SPAG7 MSH2 CDCA8 PPP1CA PPP1CC DNAH1 GTF2F1 TSR1 PHF3 MPHOSPH8 PDZD2	5.52e-06	901	273	30	int:H3C1
Interaction	YWHAG interactions	GPHN GTPBP4 SF3B4 RIMKLA MYO9A RASSF2 TRIP11 FAM13B MEF2D DDX3X SPICE1 CRACD NF1 RBM15B RABGEF1 NKTR TSC22D4 CAMSAP1 DNMBP MAP4K4 UBFD1 CDC42BPA CARMIL1 NCKAP5L PPP1CA AAR2 NHSL1 LMO7 PHF3 ANKRD34A CEP131 LRBA CDC25A CSPP1 PCDH7 USP6NL ATP5F1A	6.09e-06	1248	273	37	int:YWHAG
Interaction	MAPRE3 interactions	FILIP1 PPP1R13L SPICE1 LARP4B DIAPH3 CAMSAP1 DNMBP MAP4K4 MARCHF7 REL NCKAP5L LMO7 CEP131	1.64e-05	230	273	13	int:MAPRE3
Interaction	CD2BP2 interactions	SF3B4 SF3A1 MECP2 NFX1 NKTR MGA SF3B2 KIF22 GINS3 SGTA PPP1CA AAR2 PPP1CC	1.79e-05	232	273	13	int:CD2BP2
Interaction	VPS33B interactions	DDX3X SPICE1 CAMSAP1 DNMBP MAP4K4 MIA3 NCKAP5L NBAS LMO7 NCOA7 CEP131 CSPP1	1.83e-05	199	273	12	int:VPS33B
Interaction	HRAS interactions	SF3B4 RASSF2 ADD2 NF1 NRK RABGEF1 MMS19 DIAPH3 CAMSAP1 MAP4K4 ZDHHC18 CDC42BPA MSH2 GRIN2D ECPAS CDCP1 LLGL1 SLC16A1 SUSD5 PARVA LRBA CDC25A PCDH7 USP6NL PLCE1	1.95e-05	725	273	25	int:HRAS
Interaction	SLC6A4 interactions	EPPK1 LZTS3 MYO9A VPS13C VPS16 ADGRV1 GALNT16 ITIH1 ADD2 NF1 CASKIN1 DLG2 SYT5 ALG2 PPP1CA LLGL1 CSNK1D CDH2	3.13e-05	437	273	18	int:SLC6A4
Interaction	CECR2 interactions	ZNF318 MECP2 MLKL SOX7 UXT CECR2	3.48e-05	46	273	6	int:CECR2
Interaction	HSD17B14 interactions	PIDD1 AGO4 CIAO2A MGA MIA3 REL	4.45e-05	48	273	6	int:HSD17B14
Interaction	FBXO22 interactions	BDP1 ZHX3 DCHS2 ACACB OBSCN ACTL6A NEB DYSF RYR3 COPS8 GNL2 MAP4K4 CARMIL1 ECPAS PPP1CA AAR2 LMO7 LRBA CSPP1 HYDIN	5.12e-05	540	273	20	int:FBXO22
GeneFamily	Fibronectin type III domain containing	BOC MYLK OBSCN PTPRD PTPRS FNDC9 IL31RA COL12A1 DSCAM IGSF9B MYBPC2	8.34e-07	160	186	11	555
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	BOC MYLK OBSCN IGSF10 PTPRD PTPRS ALPK3 DSCAM IGSF9B MYBPC2	6.61e-06	161	186	10	593
GeneFamily	Galectins	LGALS9C LGALS9B LGALS9	4.45e-04	15	186	3	629
GeneFamily	Fibronectin type III domain containing\|USH2 complex	ADGRV1 WHRN	6.23e-04	4	186	2	1244
GeneFamily	Dyneins, axonemal	DNAH2 DNAH1 DNAH11	6.55e-04	17	186	3	536
GeneFamily	PDZ domain containing	IL16 GIPC2 DLG2 WHRN PRX LMO7 PDZD2	1.01e-03	152	186	7	1220
GeneFamily	Cytosolic iron-sulfur assembly components	MMS19 CIAO2A	1.54e-03	6	186	2	1028
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	LGALS9C ABCA2 MYLK LGALS9B RASSF2 MATN2 KATNAL1 SRCAP TRIP11 ABCA7 MECP2 FRMD4B BMP1 AGO4 CDH20 NR1D2 UBFD1 DNMT3B GINS3 DSCAM FAM13C CCDC28A PRAMEF4 ECPAS AAR2 LGALS9 NHSL1 KANSL1 YLPM1 IGSF9B SLC2A13 ATP1B2 PCDH7 USP6NL	5.08e-08	1124	280	34	MM1070
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	ABCA2 MYLK RASSF2 MATN2 KATNAL1 SRCAP TRIP11 ABCA7 MECP2 FRMD4B BMP1 AGO4 CDH20 NR1D2 UBFD1 DNMT3B GINS3 DSCAM FAM13C CCDC28A ECPAS AAR2 LGALS9 NHSL1 KANSL1 YLPM1 IGSF9B SLC2A13 ATP1B2 PCDH7 USP6NL	9.78e-07	1102	280	31	M2369
Coexpression	GSE26727_WT_VS_KLF2_KO_LPS_STIM_MACROPHAGE_UP	AUH SRCAP SPICE1 MICA TSC22D4 GPI CASP4 ST3GAL1 CTSA LMO7 MAPK11 PCDH7	1.71e-06	199	280	12	M8301
Coexpression	MURARO_PANCREAS_BETA_CELL	GPRASP1 ZHX3 GLT8D2 RIMKLA VPS13C ZNF318 KATNAL1 TRIP11 ADM CRACD SCAPER NR1D2 CACNA1D MIA3 CDC42BPA ECPAS CDCP1 ALG2 MADD USF3 DDX3Y MPHOSPH8 SLC2A13 ATP1B2 YME1L1 PCDH7 PDZD2	3.92e-06	946	280	27	M39169
Coexpression	YAGI_AML_WITH_INV_16_TRANSLOCATION	TPT1 ZNF318 FRMD4B SLC38A10 NF1 SLC25A40 RBM15B DLG2 CACNA1D MED6 DIDO1 NLRP1 LFNG LGALS9 CSNK1D BCAM	1.02e-05	411	280	16	M1047
Coexpression	GSE20366_TREG_VS_NAIVE_CD4_TCELL_DEC205_CONVERSION_DN	ADGRV1 DYSF TRIP11 SPICE1 ASB8 ADAMTS15 NKPD1 LFNG PBX3 CDH2 EPB42	1.11e-05	200	280	11	M4334
Coexpression	WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2	ADM BMP1 MICB MICA DNMT3B LFNG	3.24e-05	57	280	6	M2316
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN ADGRV1 NEB RYR3 PTPRD NRK PKHD1 COL12A1 ZAN SALL4 DNAH1 MYO15A HYDIN PLCE1 DNAH11	8.72e-13	184	280	15	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN ADGRV1 NEB RYR3 PTPRD NRK PKHD1 COL12A1 ZAN SALL4 DNAH1 MYO15A HYDIN PLCE1 DNAH11	8.72e-13	184	280	15	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	OBSCN ADGRV1 NEB RYR3 PTPRD NRK PKHD1 COL12A1 ZAN SALL4 DNAH1 MYO15A HYDIN PLCE1 DNAH11	8.72e-13	184	280	15	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FILIP1 VPS13C TMEM215 TRIP11 SLC38A10 SCAPER PKM NKTR MGA CACNA1D MIA3 MADD DDX3Y CDH2	2.83e-11	195	280	14	7796ea9247f4c63762f0de8490fed08b9717fa23
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	FILIP1 VPS13C TMEM215 SLC38A10 SCAPER PKM NKTR MGA CACNA1D MIA3 MADD DDX3Y CDH2	3.65e-10	195	280	13	3e519cffa6144a62b06124642a14c9ff39b76554
ToppCell	LPS-IL1RA+antiTNF\|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	AUH MYO9A IGSF10 DLG2 CACNA1D FBLN5 CECR2 LMO7 PHF3 DDX3Y LRBA PCDH7	1.45e-09	177	280	12	b7fee75de7e96924af488a5baa2334711889ae7c
ToppCell	10x3'2.3-week_12-13-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 GALNT16 TRIL NRK FLNC FBLN5 COL12A1 FAM13C LAMA2 PCDH7	5.77e-09	200	280	12	fee22a6a6c7b93af204b5b56f2c34f1411500e18
ToppCell	facs-Diaphragm-Limb_Muscle-24m\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TPT1 ADGRV1 RYR3 PKHD1 MMP3 CELF6 ZAN DSCAM DNAH1 HYDIN DNAH11	1.08e-08	169	280	11	12bdc709bc000d7f9061ecd9fbd57233eaacb7e2
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZHX3 AHI1-DT MYO9A NRK PKHD1 DIAPH3 SLC2A13 PBX3 HYDIN PDZD2 DNAH11	2.91e-08	186	280	11	f0c8de4f6ae9047b9108a47a2af8c5f42bc103b0
ToppCell	10x5'v1-week_14-16-Mesenchymal_fibro\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 GALNT16 NRK DLG2 FBLN5 COL12A1 FAM13C LAMA2 PLCE1	3.43e-08	189	280	11	40764f461b8aa1d3a2c5a30590b7fb9307d47d09
ToppCell	10x5'v1-week_14-16-Mesenchymal_fibro-stroma\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 GALNT16 NRK DLG2 FBLN5 COL12A1 FAM13C LAMA2 PLCE1	3.43e-08	189	280	11	eccf3d49354a67c94f1ed7c15a98a48a5e8e2ed0
ToppCell	droplet-Lung-1m-Mesenchymal-fibroblast-adventitial_fibroblast\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	BOC GLT8D2 GALNT16 IGSF10 BMP1 DLG2 MMP3 FLNC ITGA11 FBLN5 LAMA2	4.03e-08	192	280	11	f9fb24457999dc9e751a099d7f995543b9330ad4
ToppCell	10x5'v1-week_12-13-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC GALNT16 TRIL NRK TAS2R50 FLNC FBLN5 COL12A1 FAM13C LAMA2 IGSF9B	4.25e-08	193	280	11	3d85c28f6ebdcb15e875ad01d52d6c138fbf8525
ToppCell	Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_immune_recruiting\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	BOC MATN2 GALNT16 TRIL PTPRD POGLUT2 ITGA11 FBLN5 DDX3Y ATP1B2 PCDH7	5.25e-08	197	280	11	31c8d6e565bbdc37843ce871fe91845b0cc18a9f
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	GPHN MYO9A ADGRV1 NF1 PTPRD SCAPER DLG2 NHSL1 KANSL1 LRBA PDZD2	5.52e-08	198	280	11	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	10x3'2.3-week_12-13-Mesenchymal_fibro\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 GALNT16 NRK FLNC FBLN5 COL12A1 FAM13C LAMA2 PCDH7	6.12e-08	200	280	11	76f3043cb88071256ff661885fe5a82a54f5b733
ToppCell	10x3'2.3-week_12-13-Mesenchymal_fibro-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 GALNT16 NRK FLNC FBLN5 COL12A1 FAM13C LAMA2 PCDH7	6.12e-08	200	280	11	64d2941689d7ca8af54f9ba21c5aeabf719084ef
ToppCell	Adult-Mesenchymal-myofibroblast_cell\|Adult / Lineage, Cell type, age group and donor	BOC GIPC2 MYLK KCNB2 GALNT16 CRACD FAM13C LAMA2 ATP1B2 ADAMTSL2	1.11e-07	167	280	10	d584a8548a5317bd9686b3be8246ae6ed568796b
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A ADGRV1 KCNB2 NRK PKHD1 DIAPH3 COL12A1 SLC2A13 CDH2 PDZD2	2.35e-07	181	280	10	9d782ba5cf5a172cb4f447763fc50e5b13ef7dd9
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A KCNB2 PTPRD PKHD1 ADAMTS15 DLG2 DIAPH3 SLC2A13 CDH2 HYDIN	2.35e-07	181	280	10	6956ecd6264f7469a25e555673bce4eb97d28f7a
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_3\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MYO9A ADGRV1 KCNB2 NRK PKHD1 DIAPH3 COL12A1 SLC2A13 CDH2 PDZD2	2.48e-07	182	280	10	eb138aa1dca9373f1586600f258df06dcf56d81f
ToppCell	LV-15._Ventricular_Cardiomyocyte_III\|LV / Chamber and Cluster_Paper	FILIP1 ACACB OBSCN DLG2 FLNC LAMA2 LMO7 CDH2 PCDH7 PDZD2	2.74e-07	184	280	10	ab7a1620c14a9d9b6be1b47c559931e345e9eef8
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BOC AHI1-DT MYO9A PKHD1 ADAMTS15 SLC2A13 BCAM CDH2 HYDIN DNAH11	2.74e-07	184	280	10	da06ff24ee2b2cf4715fdfce43030b2da9e0aaf8
ToppCell	(5)_Pericytes-(50)_Pericytes\|World / Cell class and subclass of bone marrow stroma cells in homeostatis	FILIP1 MYLK MAP3K7CL GALNT16 ADAMTS15 SYT5 NRIP2 BCAM ATP1B2 PLCE1	3.03e-07	186	280	10	67b59defdd1ed3608229cc5e2a3b480d92312afa
ToppCell	(5)_Pericytes\|World / Cell class and subclass of bone marrow stroma cells in homeostatis	FILIP1 MYLK MAP3K7CL GALNT16 ADAMTS15 SYT5 NRIP2 BCAM ATP1B2 PLCE1	3.03e-07	186	280	10	acbca8cc048d87faf859b3e77bdb38d0a3dad71c
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYLK MAP3K7CL TMEM215 SYT5 SPINDOC NPAS2 NRIP2 SUSD5 ATP1B2 PLCE1	3.18e-07	187	280	10	9688141beef4f62613d7a810c5872ccb9afc1a71
ToppCell	droplet-Heart-4Chambers-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYLK MAP3K7CL TMEM215 SYT5 SPINDOC NPAS2 NRIP2 SUSD5 ATP1B2 PLCE1	3.18e-07	187	280	10	dba4924d914a7dcd4901142684ba920c2404860b
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Degenerative_Descending_Thin_Limb_Cell_Type_3\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZHX3 AHI1-DT MYO9A NRK PKHD1 DIAPH3 SLC2A13 PBX3 HYDIN PDZD2	3.18e-07	187	280	10	c31130fc2f9f882944b2ba366a034a03f051c4b9
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BOC AHI1-DT MYO9A PKHD1 ADAMTS15 DIAPH3 SLC2A13 CDH2 HYDIN DNAH11	3.51e-07	189	280	10	904b8337e2cabac2f0bf5dad5598fc429581ed81
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|RV / Chamber and Cluster_Paper	FILIP1 ACACB OBSCN DLG2 LAMA2 SLC4A3 LMO7 CDH2 PCDH7 PDZD2	3.69e-07	190	280	10	fe8e78922c8ae928ef9a80bffd67868d5a87a091
ToppCell	10x5'v1-week_14-16-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_14-16 / cell types per 3 fetal stages;per 3',per 5'	BOC GLT8D2 MATN2 NRK DLG2 FBLN5 COL12A1 FAM13C LAMA2 PLCE1	3.87e-07	191	280	10	5271198116343c07202649889057e5774d7fdde3
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MYLK MAP3K7CL TMEM215 GALNT16 NPAS2 FLNC SUSD5 ATP1B2 CDH2 PCDH7	4.06e-07	192	280	10	2cc712186e37fb21a964c032765c36a8b4a852cf
ToppCell	NS-moderate-d_0-4\|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	FILIP1 CFAP251 ADGRV1 IGSF10 DNAH2 BCAM CSPP1 PCDH7 HYDIN DNAH11	4.26e-07	193	280	10	ea345d34440b25f65358a53dc72831998d1c3620
ToppCell	PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK MAP3K7CL TMEM215 GALNT16 ADAMTS15 SUSD5 ATP1B2 CDH2 PCDH7 PDZD2	4.26e-07	193	280	10	88916d9a7d831eb52848599917c04238f8f9812b
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	IL16 MYLK PTPRS ADAMTS15 CACNA1D FBLN5 LAMA2 HIVEP3 PCDH7 ADAMTSL2	4.26e-07	193	280	10	99525545552b371c86b18b6ea6f4897dc6e9a9ec
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	IL16 MYLK PTPRS ADAMTS15 CACNA1D FBLN5 LAMA2 HIVEP3 PCDH7 ADAMTSL2	4.26e-07	193	280	10	b3ad5ff480d99217f36cc7471e5a96a519ddb409
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	4.68e-07	195	280	10	dd281a249854800f737dc22e0f375f66dfb5cf5f
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	4.68e-07	195	280	10	49c99553629cdd83ee56a2e508d5bc8d34b8507b
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK MAP3K7CL TMEM215 GALNT16 ADAMTS15 NRIP2 SUSD5 ATP1B2 CDH2 PCDH7	4.68e-07	195	280	10	c51b1bee79e77aa2ac444a4883ef533c0095eaad
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	BOC IL16 MYLK IGSF10 PTPRS ADAMTS15 CACNA1D FBLN5 LAMA2 PCDH7	4.91e-07	196	280	10	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	GPHN MYO9A ADGRV1 PTPRD SCAPER DLG2 HIVEP3 KANSL1 LRBA PDZD2	4.91e-07	196	280	10	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	4.91e-07	196	280	10	fa445f4240c521cf04eb2e2f79a5c55fda31209a
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	4.91e-07	196	280	10	802f61e78a9a1030a86c4a980c398a73cd4d1574
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	FILIP1 MYLK FRMD4B IGSF10 PTPRD CACNA1D CARMIL1 LAMA2 PCDH7 CDH12	5.14e-07	197	280	10	0034bae02ee7fcfea520d453ca3c842ab6963b12
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	IL16 MYLK FRMD4B CRACD PTPRD DLG2 CACNA1D LAMA2 HIVEP3 PCDH7	5.14e-07	197	280	10	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	distal-mesenchymal-Fibromyocyte-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	BOC GLT8D2 MYLK KCNB2 FBLN5 FAM13C THSD7B CDH2 PCDH7 EPB42	5.38e-07	198	280	10	9d1d95e7703cfc70a8ad427e400c340dbd205db8
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW19-Stem_cells\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	BOC MYLK KATNAL1 ADGRV1 MKI67 DIAPH3 FOXM1 GINS3 CDCA8 GMNN	5.38e-07	198	280	10	dc0c6189ff9dd76675f63acf1cbc7dda60e75f3f
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW19-Stem_cells-Stem_cells\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	BOC MYLK KATNAL1 ADGRV1 MKI67 DIAPH3 FOXM1 GINS3 CDCA8 GMNN	5.38e-07	198	280	10	50f236ab7ef6f00721f6cd714e3eee183077beeb
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FILIP1 MYLK KCNB2 DYSF ALPK3 FLNC FAM13C IGSF9B PCDH7 DNAH11	5.38e-07	198	280	10	c12e7511628db819a52959bb68580e27c00c2e41
ToppCell	Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	FILIP1 MYLK KCNB2 DYSF ALPK3 FLNC FAM13C IGSF9B PCDH7 DNAH11	5.38e-07	198	280	10	22e766df1276c5b14aa0d83f434f47140ebb98ea
ToppCell	distal-mesenchymal-Fibromyocyte\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	BOC GLT8D2 MYLK KCNB2 FBLN5 FAM13C THSD7B CDH2 PCDH7 EPB42	5.38e-07	198	280	10	fbfac1d10e4224990a094cc84b74bbc206881423
ToppCell	Adult-Mesenchymal-myofibroblast_cell-D122\|Adult / Lineage, Cell type, age group and donor	BOC GPRASP1 GIPC2 KCNB2 CRACD FBLN5 FAM13C LAMA2 ADAMTSL2	7.36e-07	158	280	9	410fa08c9d880d27e80ec939fa5ba5a41dcb31ab
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADGRV1 SAXO1 RYR3 PKHD1 COL12A1 CECR2 LAMA2 C2orf74 HYDIN	8.18e-07	160	280	9	c381ec6be8cf887861cc18f831a20db42f953fe1
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADGRV1 SAXO1 RYR3 PKHD1 COL12A1 CECR2 LAMA2 C2orf74 HYDIN	8.18e-07	160	280	9	25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585
ToppCell	Transplant_Alveoli_and_parenchyma-Epithelial-Basal_2\|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X	DCHS2 TRIM29 ADAMTS15 MMP3 CNDP1 KLK11 MAPK11 CDH2 PCDH7	9.55e-07	163	280	9	f21951e63188eb0c04675a8f81a0da495c26c007
ToppCell	droplet-Lung-30m-Hematologic-myeloid-myeloid_dendritic_cell-proliferating_dendritic\|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	OPN3 STRIP2 DLG2 KIF22 ITGA11 DSCAM CARMIL1 KCTD14 CDC25A	1.49e-06	172	280	9	b043d4f81dced7fb3326043f68474123be47cc5d
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MEF2D NRIP2 FLNC COL12A1 BRSK2 SUSD5 PLCE1	1.57e-06	173	280	9	901b8e6909c1f3849906fad9cee17b8f0bab050d
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MYLK MEF2D NRIP2 FLNC COL12A1 BRSK2 SUSD5 PLCE1	1.57e-06	173	280	9	fc2602b2ce051cd4c33957d7e3d041ff8a529883
ToppCell	facs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EPPK1 MYLK MAP3K7CL MKI67 SYT5 NRIP2 HEXIM2 SUSD5 PLCE1	1.72e-06	175	280	9	cf15465855602ba135752c18755e3e058dbd42ec
ToppCell	facs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	EPPK1 MYLK MAP3K7CL MKI67 SYT5 NRIP2 HEXIM2 SUSD5 PLCE1	1.72e-06	175	280	9	d8e385320f554d974538b7cdc4f8e4767f1455f2
ToppCell	PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAP3K7CL KCNB2 GALNT16 MKI67 KIF22 CDCA8 ANKRD34A ATP1B2 PCDH7	1.81e-06	176	280	9	75412d58438d71c49a6096bb2ef12b7f349653d8
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	BOC MYO9A PKHD1 ADAMTS15 DIAPH3 SLC2A13 CDH2 HYDIN DNAH11	1.81e-06	176	280	9	327a3e81b724252e36d786de92a3ffd721ea6d7b
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYLK OPN3 KCNB2 RYR3 MAP4K4 CDCP1 HIVEP3 CDH2 CDH12	1.98e-06	178	280	9	a0ab20c588e7d43d0320d4779d9ab95c1c86e297
ToppCell	facs-Heart-RV-24m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYLK MAP3K7CL CASKIN1 NRIP2 SLC4A3 SUSD5 IGSF9B ATP1B2 PLCE1	2.17e-06	180	280	9	a37cc885fe3f6cb9df69d43358064c83c18412e7
ToppCell	facs-Heart-RV-24m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYLK MAP3K7CL CASKIN1 NRIP2 SLC4A3 SUSD5 IGSF9B ATP1B2 PLCE1	2.17e-06	180	280	9	63a6d532b16b8b15c7c9102148d7297ee3afd641
ToppCell	PBMC-Mild-cDC_2\|Mild / Compartment, Disease Groups and Clusters	EPPK1 GIPC2 RIMKLA ITIH1 CRACD PTPRD ATP1B2 PDZD2	2.28e-06	135	280	8	cb9d834f8301cf53f20e09c3f4cb6a148690196a
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	BOC PTPRD PKHD1 ADAMTS15 DIAPH3 SLC2A13 CDH2 HYDIN DNAH11	2.38e-06	182	280	9	5e1b316599436740f1b30875f0ebd33c3edfb2b6
ToppCell	Pericytes-IPF_02\|World / lung cells shred on cell class, cell subclass, sample id	MYLK GALNT16 ITIH1 NRIP2 FLNC FAM13C BRSK2 SUSD5 ATP1B2	2.60e-06	184	280	9	cd10d351d91a81dd6dc806cb4e0c8d7861c98e0b
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l39\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MAP3K7CL TMEM215 GALNT16 FLNC BRSK2 SUSD5 IGSF9B ATP1B2 PCDH7	2.97e-06	187	280	9	218c9b4f28499389c43005d9626af2ac01066027
ToppCell	droplet-Lung-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	MAP3K7CL TMEM215 GALNT16 FLNC BRSK2 SUSD5 IGSF9B ATP1B2 PCDH7	2.97e-06	187	280	9	c7ac4b328efc2ebb72f71154661914193ff402ca
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZHX3 AHI1-DT MYO9A ADGRV1 PKHD1 DIAPH3 SLC2A13 HYDIN PDZD2	3.11e-06	188	280	9	af740fa78542438fdff627ea1f74f4eee43316be
ToppCell	droplet-Lung-LUNG-1m-Mesenchymal-adventitial_cell\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BOC GLT8D2 MATN2 GALNT16 IGSF10 BMP1 DLG2 ITGA11 LAMA2	3.24e-06	189	280	9	f0a2d4ef9896d764971ebbc6952510c128bb76e8
ToppCell	RV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	FILIP1 ACACB OBSCN DLG2 LAMA2 LMO7 CDH2 PCDH7 PDZD2	3.24e-06	189	280	9	5e80c47f63980904c4c1ff02c201b67b456a0974
ToppCell	droplet-Lung-LUNG-1m-Mesenchymal-Adventitial_Fibroblast\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BOC GLT8D2 MATN2 GALNT16 IGSF10 BMP1 DLG2 ITGA11 LAMA2	3.24e-06	189	280	9	378f26f751ab4b470948c35dd8347de72dd12ff7
ToppCell	Somatosensory_Cortex_(S1)-Non-neuronal-Macroglial\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ACACB RASSF2 FRMD4B HEPACAM CDH20 TSC22D4 CNDP1 CECR2 NHSL1	3.39e-06	190	280	9	07f21386ea6eb23416a537d2250e3042efe93fb0
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|World / Chamber and Cluster_Paper	FILIP1 ACACB OBSCN DLG2 LAMA2 LMO7 CDH2 PCDH7 PDZD2	3.39e-06	190	280	9	de5ef606a002f85c2e0e3a36c1f259d0b85a76ff
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	3.54e-06	191	280	9	107113b930d9ad171f1b2aa20df4567c94fae7d8
ToppCell	Primary_Motor_Cortex_(M1)-Non-neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	RASSF2 FRMD4B HEPACAM CDH20 TSC22D4 CNDP1 WHRN CECR2 NHSL1	3.54e-06	191	280	9	2b056cbe2e82e056e1f798974999378460eb1d16
ToppCell	LV-06._Ventricular_Cardiomyocyte_II\|LV / Chamber and Cluster_Paper	FILIP1 ACACB OBSCN DLG2 LAMA2 LMO7 CDH2 PCDH7 PDZD2	3.54e-06	191	280	9	25f3eb34f4e70761e81e84c8a5829f216108cbc6
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 MATN2 CRACD ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	3.54e-06	191	280	9	bc353a79a1d11ca52bba5e3874a80d432e1a7715
ToppCell	10x5'v1-week_12-13-Mesenchymal_fibro-stroma\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC MATN2 GALNT16 TRIL NRK FLNC FBLN5 COL12A1 LAMA2	3.69e-06	192	280	9	4ed5040594ba2d0639f0990697504ecef872ca70
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BOC FILIP1 MATN2 ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	3.69e-06	192	280	9	5105e4b577408b4e1a62d0a44c23c2b830ccad88
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 LHFPL1 MEF2D OSBPL5 NRIP2 CARMIL1 SUSD5 IGSF9B PLCE1	3.69e-06	192	280	9	bfab13793e54de2550ee171397f7ece0625cdb4a
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 LHFPL1 MEF2D OSBPL5 NRIP2 CARMIL1 SUSD5 IGSF9B PLCE1	3.69e-06	192	280	9	b54b0d5b88139905521c8d5d58332e89c08d589c
ToppCell	5'-GW_trimst-2-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DCHS2 MATN2 TRIL PTPRD NRK FBLN5 ARSF ATP1B2 PBX3	3.69e-06	192	280	9	20ede290e01ad574afd122d72b59dbc52c595fad
ToppCell	10x5'v1-week_12-13-Mesenchymal_fibro\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	BOC MATN2 GALNT16 TRIL NRK FLNC FBLN5 COL12A1 LAMA2	3.69e-06	192	280	9	d4f5d6653564c2c5d0f5f7c932d89cb1b1412844
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	BOC FILIP1 MATN2 ITGA11 FBLN5 COL12A1 LAMA2 PCDH7 ADAMTSL2	3.69e-06	192	280	9	d3c1ad4667a1e223a83ca0fcd5991a0b96f1199a
ToppCell	Pericytes\|World / lung cells shred on cell class, cell subclass, sample id	MYLK GALNT16 ITIH1 NRIP2 FLNC FAM13C BRSK2 SUSD5 ATP1B2	3.69e-06	192	280	9	057ad22b878c0c5fb59ed1412ca13db945c57a5a
ToppCell	droplet-Heart-HEART-1m-Mesenchymal-smooth_muscle_cell\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYLK MAP3K7CL TMEM215 NR1D2 NRIP2 SUSD5 BCAM ATP1B2 PLCE1	3.69e-06	192	280	9	eb9a0b3d32f90f8b95905c740aab21639dae5cbd
ToppCell	Mesenchymal-matrix_fibroblast_2_cell\|World / Lineage, Cell type, age group and donor	BOC GLT8D2 MATN2 IGSF10 NRK ADAMTS15 COL12A1 LAMA2 PCDH7	3.69e-06	192	280	9	a769158c49d2b208c4224d85e7ae68c85cc372ed
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DCHS2 MATN2 TRIL NRK FBLN5 ARSF ATP1B2 PBX3 MYBPC2	3.85e-06	193	280	9	7cd9671e0ac64f7f3607f564485c63abbb7e7a63
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAP3K7CL TMEM215 ADAMTS15 NRIP2 FBLN5 SUSD5 ATP1B2 PCDH7 PLCE1	3.85e-06	193	280	9	323d1f3f4fbeb93ba857fc135d8aa0b897f98ac5
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK MAP3K7CL TMEM215 GALNT16 SUSD5 ATP1B2 CDH2 PCDH7 PDZD2	3.85e-06	193	280	9	800b0f5705fefcd3608e37801afae8a94474723e
ToppCell	E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MAP3K7CL TMEM215 NRIP2 FBLN5 SUSD5 ATP1B2 CDH2 PCDH7 PLCE1	3.85e-06	193	280	9	469a7f1c2ff7137cc5a064464456911f67f92e70
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 CFAP251 MATN2 CRACD PTPRS ITGA11 FBLN5 LAMA2 ADAMTSL2	4.01e-06	194	280	9	81713e0409e8be695ba5dfdc67a997b33435dd9e
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	IL16 MYLK PTPRS ADAMTS15 CACNA1D FBLN5 LAMA2 HIVEP3 ADAMTSL2	4.01e-06	194	280	9	e93de9428c986b8943fc169258847c650cfab0e5
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FILIP1 CFAP251 MATN2 CRACD PTPRS ITGA11 FBLN5 LAMA2 ADAMTSL2	4.01e-06	194	280	9	627cffe2d448e74fc5df92e74e5b922a73304137
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ADGRV1 DYSF GALNT16 RYR3 ADM PTPRD ZDHHC18 THSD7B MYO15A	4.19e-06	195	280	9	19853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ADGRV1 DYSF GALNT16 RYR3 ADM PTPRD ZDHHC18 THSD7B MYO15A	4.19e-06	195	280	9	d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell	PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYLK MAP3K7CL GALNT16 ADAMTS15 NRIP2 SUSD5 ATP1B2 CDH2 PCDH7	4.19e-06	195	280	9	43d372373367b71243c6ea958aedccde4478618f
Drug	Diflorasone Diacetate [33564-31-7]; Up 200; 8uM; PC3; HT_HG-U133A	ABCA2 SRCAP NEB TRIM29 MEF2D BMP1 NF1 MIA2 SCAPER NFX1 CAMSAP1 NLRP1 MAPK11	9.52e-07	197	277	13	4077_UP
Drug	0173570-0000 [211245-44-2]; Up 200; 10uM; MCF7; HT_HG-U133A	LZTS3 SRCAP NF1 NKTR KLK11 WHRN CDC42BPA DSCAM FAM13C MYO15A CDH2 PLCE1	4.63e-06	193	277	12	4712_UP
Drug	Prazosin hydrochloride [19237-84-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	ZNF318 SPICE1 NF1 PTPRS FGD1 PRX LLGL1 PHF3 PARVA PCDH7 HCLS1 PDZD2	5.72e-06	197	277	12	6475_UP
Drug	Dioxybenzone [131-53-3]; Up 200; 16.4uM; MCF7; HT_HG-U133A	SRCAP ABCA7 BMP1 ZFYVE9 SCAPER FGD1 TSC22D4 WHRN CDC42BPA ATP1B2 CSPP1 PDZD2	6.34e-06	199	277	12	6478_UP
Drug	Pipemidic acid [51940-44-4]; Up 200; 13.2uM; PC3; HT_HG-U133A	DCHS2 IL16 SRCAP ABCA7 MEF2D ACTL8 DLG2 CASP4 NLRP1 LLGL1 PARVA KCTD14	6.34e-06	199	277	12	6752_UP
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	GTPBP4 ABCA2 EPPK1 SRCAP NF1 FGD1 TSC22D4 DSCAM PHF3 CDC25A CSPP1	2.61e-05	193	277	11	1464_DN
Drug	Methylhydantoin-5-(L) [40856-73-3]; Down 200; 35uM; MCF7; HT_HG-U133A	ABCA2 LZTS3 SRCAP DYSF TRIP11 NF1 NFX1 CAMSAP1 WHRN CDC42BPA BCAM	2.61e-05	193	277	11	3378_DN
Drug	Thonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A	ZHX3 ABCA2 GIPC2 MYLK BMP1 FGD1 MMP3 WHRN CDC42BPA PHF3 BCAM	2.73e-05	194	277	11	6457_UP
Drug	0317956-0000 [391210-11-0]; Up 200; 10uM; MCF7; HT_HG-U133A	SRCAP TRIM29 ADD2 NKTR NR1D2 WHRN CACNA1D CASP4 PRX HIVEP3 LLGL1	2.73e-05	194	277	11	3855_UP
Drug	Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A	GPRASP1 ABCA2 EPPK1 ADM ZFYVE9 SCAPER NR1D2 REL GTF2F1 PHF3 CSPP1	2.73e-05	194	277	11	3274_DN
Drug	Cocaine	GPRASP1 ZHX3 LZTS3 OBSCN NEB GALNT16 MECP2 MEF2D RYR3 NF1 PKM DLG2 SYT5 DNMBP DNMT3B NPAS2 WHRN VWF CASP4 MARCHF7 REL GRIN2D SLC4A3 PPP1CA LMO7 PARVA PDCD11 MAPK11 PBX2 CDC25A ATP1B2 PBX3 PCDH7 ATP5F1A	2.78e-05	1314	277	34	ctd:D003042
Drug	Benperidol [2062-84-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A	GPHN AUH FAM13B DDX3X LARP4B NKTR MED6 CARMIL1 SLC16A1 DPY19L4 USP6NL	2.87e-05	195	277	11	4781_DN
Drug	Amethopterin (R,S) [59-05-2]; Up 200; 8.8uM; MCF7; HT_HG-U133A	MYLK SRCAP TRIM29 NF1 MIA2 ACTL8 MMP3 CAMSAP1 MIA3 DNAH2 LLGL1	3.01e-05	196	277	11	5000_UP
Drug	Salbutamol [18559-94-9]; Down 200; 16.8uM; HL60; HT_HG-U133A	MECP2 COPS8 SCAPER YIPF6 NR1D2 BRWD1 ST3GAL1 SLC16A1 PHF3 PDCD11 CEP131	3.01e-05	196	277	11	2344_DN
Drug	Heliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A	ZHX3 ABCA2 NF1 ACTL8 PTPRS NKTR CAMSAP1 WHRN CACNA1D ECPAS CDC25A	3.01e-05	196	277	11	4739_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; HL60; HT_HG-U133A	PIDD1 ZNF318 MECP2 MEF2D NFX1 YIPF6 SGTA ST3GAL1 MADD MZF1 PHF3	3.01e-05	196	277	11	2351_DN
Drug	Graveoline [485-61-0]; Down 200; 14.4uM; PC3; HT_HG-U133A	ZHX3 ABCA2 LZTS3 MAP3K7CL SRCAP TRIM29 ZFYVE9 MIA2 WHRN CASP4 HIVEP3	3.01e-05	196	277	11	4276_DN
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; PC3; HT_HG-U133A	NEB ABCA7 DDX3X BMP1 NF1 WHRN DSCAM BRSK2 SLC4A3 PARVA BCAM	3.01e-05	196	277	11	5088_UP
Drug	Pyrazinamide [ 98-96-4]; Up 200; 32.4uM; MCF7; HT_HG-U133A	ABCA2 MYO9A ATXN7L1 SRCAP NF1 ZFYVE9 CAMSAP1 WHRN MIA3 HIVEP3 CDH2	3.15e-05	197	277	11	2839_UP
Drug	Pimozide [2062-78-4]; Down 200; 8.6uM; PC3; HT_HG-U133A	GTPBP4 MYLK NF1 COPS8 FGD1 PRMT7 BRWD1 NPAS2 ACTR8 DIDO1 USP6NL	3.15e-05	197	277	11	7132_DN
Drug	PNU-0251126 [267429-19-6]; Down 200; 1uM; PC3; HT_HG-U133A	EPPK1 ACACB NF1 ZFYVE9 NFX1 FGD1 NKTR TSC22D4 ANKRD40 BRWD1 CDC42BPA	3.15e-05	197	277	11	7390_DN
Drug	Meclofenamic acid sodium salt monohydrate [6385-02-0]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ZHX3 ABCA2 APTX VPS16 BMP1 NF1 ZDHHC18 TIGD6 CEP131 CDC25A USP6NL	3.15e-05	197	277	11	7038_DN
Drug	Ethisterone [434-03-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	LZTS3 RASSF2 SRCAP TRIM29 FGD1 CACNA1D DSCAM NLRP1 HIVEP3 MAPK11 ATP1B2	3.30e-05	198	277	11	2326_UP
Drug	Merbromin [129-16-8]; Down 200; 5uM; PC3; HT_HG-U133A	SRCAP NEB MEF2D ADD2 NF1 MIA2 CASP4 NLRP1 MZF1 PARVA MAPK11	3.30e-05	198	277	11	3700_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; HL60; HT_HG-U133A	GPHN ZNF318 MECP2 FRMD4B DDX3X LARP4B YIPF6 ACTR8 MIA3 MZF1 CSPP1	3.46e-05	199	277	11	2546_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	ZHX3 MYLK TRIM29 NF1 ACTL8 NKTR CAMSAP1 BRWD1 WHRN ECPAS TIGD6	3.46e-05	199	277	11	4765_DN
Drug	Dihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; MCF7; HT_HG-U133A	ABCA2 TRIP11 BMP1 SCAPER NKTR ANKRD40 CACNA1D MED6 DSCAM SGTA AAR2	3.46e-05	199	277	11	6840_DN
Drug	Dinoprost trometamol [38362-01-5]; Down 200; 8.4uM; PC3; HT_HG-U133A	GPRASP1 ACACB ZNF318 NEB MECP2 SCAPER ZDHHC18 MZF1 YLPM1 PARVA CEP131	3.46e-05	199	277	11	6308_DN
Drug	nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A	ABCA2 EPPK1 APTX PPP1R13L NF1 ZDHHC18 DSCAM GTF2F1 MZF1 PHF3 MAPK11	3.46e-05	199	277	11	1648_DN
Drug	butirosin A from Bacillus vitellinus; Up 200; 10uM; PC3; HG-U133A	TPT1 LZTS3 ZNF318 BMP1 TSC22D4 NPAS2 CDC42BPA TSR1 MZF1 CDC25A PLCE1	3.62e-05	200	277	11	666_UP
Drug	D-cycloserine [68-41-7]; Down 200; 39.2uM; PC3; HT_HG-U133A	GTPBP4 IREB2 ZNF318 NF1 MIA2 ZDHHC18 ACTR8 MADD MZF1 SLC25A28 PLCE1	3.62e-05	200	277	11	7134_DN
Drug	VDM11	FOXM1 NLRP1 PARVA	6.01e-05	7	277	3	CID009887748
Drug	5707885; Down 200; 50uM; PC3; HT_HG-U133A	PIDD1 SRCAP MEF2D PTPRD SCAPER GINS3 CDC42BPA HIVEP3 KCTD14 BCAM	1.23e-04	191	277	10	6390_DN
Drug	Propoxycaine hydrochloride [550-83-4]; Down 200; 12uM; PC3; HT_HG-U133A	SETD6 SRCAP BMP1 NF1 COPS8 SCAPER FGD1 GINS3 BCAM CSPP1	1.28e-04	192	277	10	7155_DN
Drug	Moxalactam disodium salt [64953-12-4]; Down 200; 7uM; HL60; HT_HG-U133A	GPHN KMT2B DYSF TRIP11 MEF2D NF1 NR1D2 ACTR8 CEP131 CSPP1	1.34e-04	193	277	10	3028_DN
Drug	Pyrithyldione [77-04-3]; Down 200; 24uM; PC3; HT_HG-U133A	EPPK1 ACACB LZTS3 AUH PIDD1 NF1 PRMT7 NPAS2 MED6 BCAM	1.34e-04	193	277	10	7153_DN
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; HL60; HG-U133A	ZNF318 MEF2D ADD2 NF1 ZFYVE9 MED6 CDC42BPA SLC16A1 YLPM1 CDC25A	1.34e-04	193	277	10	1363_DN
Drug	Bromperidol [10457-90-6]; Up 200; 9.6uM; MCF7; HT_HG-U133A	PIDD1 SRCAP MEF2D BMP1 NF1 ZFYVE9 FGD1 PRX HIVEP3 PCDH7	1.34e-04	193	277	10	2872_UP
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; PC3; HT_HG-U133A	ACACB ATXN7L1 MECP2 MEF2D NF1 SCAPER WHRN ECPAS SLC4A3 CSPP1	1.34e-04	193	277	10	6646_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; SKMEL5; HG-U133A	GTPBP4 ACTL6A SRCAP GNL2 ANKRD40 GINS3 NOP16 CSNK1D LRBA CDC25A	1.34e-04	193	277	10	629_DN
Drug	forskolin; Up 200; 50uM; MCF7; HT_HG-U133A_EA	EPPK1 ACACB SRCAP MEF2D ADM DIDO1 ANKZF1 TIGD6 YLPM1	1.35e-04	157	277	9	913_UP
Drug	Tadjakonine [11087-94-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	SRCAP NEB ADM BMP1 NF1 ZFYVE9 MIA2 HIVEP3 MAPK11 PDZD2	1.40e-04	194	277	10	4424_DN
Drug	Pridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A	EPPK1 KMT2B IREB2 ZNF318 SLC38A10 MIA2 NFX1 YIPF6 MZF1 CEP131	1.40e-04	194	277	10	7214_DN
Drug	ICI 182,780; Up 200; 1uM; PC3; HT_HG-U133A	ABCA2 MAP3K7CL TRIM29 LARP4B NF1 ALPK3 NPAS2 SPAG7 SLC4A3 PHF3	1.40e-04	194	277	10	1205_UP
Drug	Tiapride hydrochloride [51012-33-0]; Down 200; 11uM; PC3; HT_HG-U133A	EPPK1 SETD6 ZNF318 SLC25A40 COPS8 PRMT7 BRWD1 ACTR8 PHF3 PLCE1	1.46e-04	195	277	10	7362_DN
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A	KMT2B ZNF318 MIA2 GNL2 BRWD1 SGTA ST3GAL1 ANKZF1 PHF3 CDC25A	1.46e-04	195	277	10	6938_DN
Drug	DCDFE-NAc	APTX NLRP1	1.47e-04	2	277	2	CID000163891
Drug	DBDFE-NAc	APTX NLRP1	1.47e-04	2	277	2	CID000164092
Drug	Aminophylline [317-34-0]; Down 200; 9.6uM; PC3; HT_HG-U133A	EPPK1 AUH PRMT7 MARCHF7 NLRP1 REL HIVEP3 PHF3 USP6NL PDZD2	1.52e-04	196	277	10	6295_DN
Drug	Alprenolol hydrochloride [13707-88-5]; Down 200; 14uM; PC3; HT_HG-U133A	GTPBP4 GPRASP1 MECP2 BMP1 PRMT7 BRWD1 REL ANKZF1 PHF3 BCAM	1.52e-04	196	277	10	7141_DN
Drug	Nitrofurantoin [67-20-9]; Down 200; 16.8uM; MCF7; HT_HG-U133A	ZHX3 MYLK DYSF NF1 MIA2 NFX1 CDC42BPA DSCAM TIGD6 MZF1	1.52e-04	196	277	10	4697_DN
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A	APTX PIDD1 DYSF TRIP11 BMP1 ZFYVE9 ACTL8 SCAPER CDC42BPA MAPK11	1.52e-04	196	277	10	6813_DN
Drug	Thiamine hydrochloride [67-03-8]; Up 200; 11.8uM; MCF7; HT_HG-U133A	ZHX3 IL16 SRCAP TRIM29 ADD2 SCAPER MMP3 CACNA1D MED6 MZF1	1.52e-04	196	277	10	7479_UP
Drug	Labetalol hydrochloride [32780-64-6]; Down 200; 11uM; MCF7; HT_HG-U133A	ACACB MECP2 NF1 NFX1 PRMT7 CACNA1D CDC42BPA BCAM MAPK11 CSPP1	1.52e-04	196	277	10	3167_DN
Drug	Diphemanil methylsulfate [62-97-5]; Down 200; 10.2uM; MCF7; HT_HG-U133A	VPS13C TRIP11 MIA2 COPS8 NFX1 FGD1 YIPF6 PHF3 BCAM CDC25A	1.52e-04	196	277	10	1494_DN
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	GTPBP4 ABCA2 PIDD1 ZNF318 ADD2 NF1 MIA2 WHRN YLPM1 MAPK11	1.58e-04	197	277	10	6940_UP
Drug	Riluzole hydrochloride; Up 200; 14.8uM; HL60; HT_HG-U133A	MYLK ZNF318 TRIP11 MEF2D ANKRD40 DNMT3B CASP4 LLGL1 DDX3Y CSPP1	1.58e-04	197	277	10	2334_UP
Drug	Dicumarol [66-76-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A	SRCAP NEB FRMD4B NF1 MIA2 MMP3 CDC42BPA SGTA YLPM1 PARVA	1.58e-04	197	277	10	3848_DN
Drug	Neostigmine bromide [114-80-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A	GTPBP4 ABCA2 LZTS3 PIDD1 TRIP11 BMP1 SCAPER CDC42BPA DSCAM MZF1	1.58e-04	197	277	10	5335_UP
Drug	Alprostadil [745-65-3]; Down 200; 11.2uM; MCF7; HT_HG-U133A	ABCA2 ZNF318 ACTL8 NFX1 CDC42BPA HIVEP3 MZF1 BCAM CSPP1 PCDH7	1.58e-04	197	277	10	7358_DN
Drug	Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Down 200; 21uM; MCF7; HT_HG-U133A	NF1 MIA2 SCAPER FGD1 MED6 CDC42BPA SGTA TSR1 MAPK11 PCDH7	1.58e-04	197	277	10	3338_DN
Drug	Propidium iodide [25535-16-4]; Down 200; 6uM; PC3; HT_HG-U133A	SRCAP ABCA7 NF1 MIA2 NKTR HIVEP3 MZF1 YLPM1 PARVA CSPP1	1.58e-04	197	277	10	5803_DN
Drug	Baclofen (R,S) [1134-47-0]; Down 200; 18.8uM; PC3; HT_HG-U133A	ZNF318 LARP4B POGLUT2 CAMSAP1 ACTR8 NLRP1 REL TSR1 MZF1 CEP131	1.58e-04	197	277	10	6313_DN
Drug	(R) -Naproxen sodium salt [26159-34-2]; Down 200; 15.8uM; PC3; HT_HG-U133A	ACACB SETD6 NF1 COPS8 FGD1 CAMSAP1 DIDO1 MARCHF7 MADD PDZD2	1.58e-04	197	277	10	7146_DN
Drug	Picotamide monohydrate [80530-63-8]; Down 200; 10.2uM; PC3; HT_HG-U133A	GLT8D2 KMT2B SCAPER MKI67 FGD1 BRWD1 ZDHHC18 CDC42BPA DIDO1 PHF3	1.58e-04	197	277	10	2070_DN
Drug	(-)-MK 801 hydrogen maleate [77086-19-2]; Up 200; 11.8uM; MCF7; HT_HG-U133A	MYLK ACACB TRIM29 SCAPER CNGB1 WHRN CDC42BPA PARVA CSPP1 HCLS1	1.65e-04	198	277	10	6458_UP
Drug	Tiaprofenic acid [33005-95-7]; Up 200; 15.4uM; HL60; HT_HG-U133A	ZHX3 TRIP11 ZFYVE9 FGD1 MMP3 GAPDHS DNMBP ACTR8 YLPM1 CDH2	1.65e-04	198	277	10	2492_UP
Drug	Dipyridamole [58-32-2]; Up 200; 8uM; PC3; HG-U133A	SRCAP TRIM29 TRIP11 MECP2 MIA2 MMS19 CAMSAP1 NBAS MZF1 MAPK11	1.65e-04	198	277	10	1934_UP
Drug	nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A	SF3A1 SRCAP NEB TRIM29 ABCA7 NF1 FGD1 CAMSAP1 DSCAM PHF3	1.65e-04	198	277	10	5583_DN
Drug	Dihydroergocristine mesylate [24730-10-7]; Down 200; 5.6uM; MCF7; HT_HG-U133A	ACACB LZTS3 PIDD1 ABCA7 TSC22D4 DSCAM MZF1 PHF3 YLPM1 BCAM	1.65e-04	198	277	10	2895_DN
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Down 200; 25.2uM; MCF7; HT_HG-U133A	ABCA2 ACACB RASSF2 SRCAP TRIM29 DYSF LARP4B ACTL8 MMP3 BCAM	1.65e-04	198	277	10	6031_DN
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; MCF7; HT_HG-U133A	GPRASP1 LZTS3 SRCAP TRIP11 BMP1 NF1 PTPRS SCAPER WHRN CACNA1D	1.65e-04	198	277	10	3895_DN
Drug	Pyridoxine hydrochloride [58-56-0]; Down 200; 19.4uM; PC3; HT_HG-U133A	EPPK1 KMT2B ZNF318 MIA2 COPS8 BRWD1 WHRN CARMIL1 PHF3 CDH2	1.65e-04	198	277	10	5813_DN
Drug	Dihydroergotoxine mesylate [8067-24-1]; Up 200; 6.4uM; PC3; HT_HG-U133A	NF1 PTPRD SCAPER NFX1 SYT5 CAMSAP1 PRX PHF3 DDX3Y MAPK11	1.65e-04	198	277	10	4071_UP
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ZHX3 ABCA2 ACACB RASSF2 SRCAP DYSF PTPRS CACNA1D MIA3 PHF3	1.65e-04	198	277	10	6053_DN
Drug	Pargyline hydrochloride [306-07-0]; Down 200; 20.4uM; MCF7; HT_HG-U133A	ABCA2 AUH SRCAP TRIP11 BMP1 SLC25A40 COPS8 BRWD1 CDC42BPA DSCAM	1.65e-04	198	277	10	7016_DN
Drug	Canrenoic acid potassium salt [2181-04-6]; Down 200; 10uM; PC3; HT_HG-U133A	GTPBP4 AUH SETD6 ANKRD40 NPAS2 ACTR8 DIDO1 MADD YLPM1 CEP131	1.65e-04	198	277	10	7135_DN
Drug	Bethanechol chloride [590-63-6]; Up 200; 20.4uM; MCF7; HT_HG-U133A	IL16 MYLK LZTS3 ZNF318 ABCA7 DDX3X BMP1 NF1 SCAPER DSCAM	1.72e-04	199	277	10	5539_UP
Drug	Amoxapine [14028-44-5]; Up 200; 12.8uM; PC3; HG-U133A	ZHX3 ZNF318 MECP2 ADD2 ZFYVE9 CDC42BPA ANKZF1 NBAS YLPM1 CDH2	1.72e-04	199	277	10	1931_UP
Drug	Flurbiprofen [5104-49-4]; Up 200; 16.4uM; HL60; HT_HG-U133A	ABCA2 ACACB VPS16 PPP1R13L TRIM29 ADD2 NPAS2 YLPM1 MYO15A PLCE1	1.72e-04	199	277	10	3095_UP
Drug	1,1-dimethylbiguanide hydrochloride; Down 200; 1000uM; MCF7; HG-U133A	TPT1 GLT8D2 KMT2B LZTS3 DYSF NF1 LAMA2 NLRP1 CEP131 SLC25A28	1.72e-04	199	277	10	4_DN
Drug	Arecoline hydrobromide [300-08-3]; Up 200; 17uM; MCF7; HT_HG-U133A	ZHX3 RASSF2 TRIM29 ABCA7 MEF2D ADM ZFYVE9 TSC22D4 CDC42BPA PARVA	1.72e-04	199	277	10	5423_UP
Drug	Isoniazid [54-85-3]; Down 200; 29.2uM; PC3; HT_HG-U133A	EPPK1 MYO9A MECP2 FGD1 BRWD1 WHRN DIDO1 SPAG7 PHF3 CEP131	1.72e-04	199	277	10	2083_DN
Drug	Denatonium benzoate [3734-33-6]; Up 200; 9uM; MCF7; HT_HG-U133A	ZNF318 NEB ADM NF1 AGO4 MMP3 CASP4 LMO7 MAPK11 CSPP1	1.79e-04	200	277	10	6502_UP
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	RASSF2 TRIM29 FRMD4B ADD2 ADM SCAPER DLG2 MIA3 BCAM PCDH7	1.79e-04	200	277	10	7534_UP
Drug	Ketotifen fumarate [34580-14-8]; Down 200; 9.4uM; PC3; HT_HG-U133A	GPRASP1 TPT1 EPPK1 ZNF318 ADD2 LARP4B FGD1 WHRN ANKZF1 HIVEP3	1.79e-04	200	277	10	5842_DN
Drug	Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A	GTPBP4 ZHX3 SRCAP NF1 ANKRD40 ZDHHC18 ANKZF1 SLC16A1 PHF3 YLPM1	1.79e-04	200	277	10	3405_DN
Disease	Malignant neoplasm of breast	BOC OBSCN ZNF318 TRIM29 DYSF GALNT16 DDX3X BMP1 NF1 CDH20 PTPRD MIA2 MKI67 MMP3 TSC22D4 DNMT3B FOXM1 GPI VWF LAMA2 GRIN2D EPG5 LLGL1 CSNK1D ANKRD34A LRBA CDH2	1.22e-06	1074	261	27	C0006142
Disease	sex interaction measurement, inflammatory bowel disease	MICB MAP4K4 CARMIL1 C2orf74 SLC34A1 SLC25A28	9.12e-06	55	261	6	EFO_0003767, EFO_0008343
Disease	aspartate aminotransferase measurement	BDP1 OBSCN ITIH1 MEF2D NF1 CDH20 PTPRD OSBPL5 PKM DNMBP NPAS2 WHRN CARMIL1 DNAH2 MARCHF7 ST3GAL1 THSD7B MADD LRBA MYO15A PLCE1	6.13e-05	904	261	21	EFO_0004736
Disease	Odontochondrodysplasia	TRIP11 MIA3	7.79e-05	2	261	2	cv:C2745953
Disease	childhood medulloblastoma (implicated_via_orthology)	DDX3X DDX3Y	7.79e-05	2	261	2	DOID:3869 (implicated_via_orthology)
Disease	triacylglycerol 54:0 measurement	NFILZ ACTL9	7.79e-05	2	261	2	EFO_0021485
Disease	azoospermia (implicated_via_orthology)	PTPRD PTPRS SCAPER CDC42BPA	8.94e-05	27	261	4	DOID:14227 (implicated_via_orthology)
Disease	susceptibility to rheumatic fever measurement	KCNB2 RYR3 PTPRD CDC25A	1.04e-04	28	261	4	EFO_0008416
Disease	Neurodevelopmental Disorders	SRCAP MECP2 DDX3X DSCAM BRSK2 HIVEP3	1.81e-04	93	261	6	C1535926
Disease	Severe Dengue	MICB PLCE1	2.32e-04	3	261	2	C0019100
Disease	Dengue Shock Syndrome	MICB PLCE1	2.32e-04	3	261	2	C0376300
Disease	glomerular filtration rate, renal transplant outcome measurement	MAP3K7CL MTIF3 SYT16 NBAS	2.52e-04	35	261	4	EFO_0005199, EFO_0005208
Disease	autosomal recessive polycystic kidney disease (implicated_via_orthology)	PKD1 PKHD1 CDC25A	3.52e-04	16	261	3	DOID:0110861 (implicated_via_orthology)
Disease	lung cancer (is_marker_for)	MEF2D MKI67 MMP3 DNMT3B	3.86e-04	39	261	4	DOID:1324 (is_marker_for)
Disease	JT interval	OBSCN FAM13B ALPK3 TSC22D4 BRWD1 CACNA1D MIA3 SLC4A3 NCOA7	3.90e-04	248	261	9	EFO_0007885
Disease	testosterone measurement	GTPBP4 ZHX3 DCHS2 ZNF318 SAXO1 SRCAP NF1 FGD1 DNMBP NR1D2 BRWD1 FOXM1 CACNA1D ZDHHC18 MIA3 ZAN DSCAM CECR2 DNAH2 AAR2 SLC34A1 MYO15A PBX2 ATP1B2	4.42e-04	1275	261	24	EFO_0004908
Disease	hereditary spherocytosis type 1 (implicated_via_orthology)	ADD2 EPB42	4.62e-04	4	261	2	DOID:0110916 (implicated_via_orthology)
Disease	Sertoli cell-only syndrome (implicated_via_orthology)	DDX3X DDX3Y	4.62e-04	4	261	2	DOID:0050457 (implicated_via_orthology)
Disease	Colorectal Carcinoma	BOC RASSF2 SF3A1 OBSCN KCNB2 NF1 PTPRD PTPRS MKI67 PKHD1 ADAMTS15 ACTL9 FLNC MSH2 HIVEP3 LMO7	5.68e-04	702	261	16	C0009402
Disease	hip geometry	ADGRV1 FRMD4B DLG2 CDH2	6.15e-04	44	261	4	EFO_0004685
Disease	Duane Retraction Syndrome	SALL4 CDH2	7.66e-04	5	261	2	C0013261
Disease	pneumonia	GIPC2 IREB2 MICA PBX3	7.91e-04	47	261	4	EFO_0003106
Disease	Alzheimer disease, polygenic risk score	PPP1R13L ABCA7 SCAPER PKHD1 DLG2 ZAN PPP1CC KANSL1 PHF3 SLC2A13 BCAM LRBA HYDIN EPB42	7.95e-04	586	261	14	EFO_0030082, MONDO_0004975
Disease	CCL2 measurement	SF3A1 ABCA7 DLG2 WHRN CDCP1 HIVEP3	9.19e-04	126	261	6	EFO_0004749
Disease	tea consumption measurement	KCNB2 FRMD4B AARS2 PKHD1 MIA3 LAMA2	1.04e-03	129	261	6	EFO_0010091
Disease	Immunologic Deficiency Syndromes	DNMT3B EPG5 NBAS	1.06e-03	23	261	3	C0021051
Disease	feeling nervous measurement	ITIH1 NF1 MGA DSCAM MADD	1.07e-03	87	261	5	EFO_0009597
Disease	Glioma	MYLK TRIM29 NF1 MSH2 ATP1B2	1.07e-03	87	261	5	C0017638
Disease	Flaccid Muscle Tone	MECP2 KANSL1	1.14e-03	6	261	2	C0026825
Disease	Unilateral Hypotonia	MECP2 KANSL1	1.14e-03	6	261	2	C0751330
Disease	Neonatal Hypotonia	MECP2 KANSL1	1.14e-03	6	261	2	C2267233
Disease	Muscle Tone Atonic	MECP2 KANSL1	1.14e-03	6	261	2	C0427202
Disease	Floppy Muscles	MECP2 KANSL1	1.14e-03	6	261	2	C0427201
Disease	cervical carcinoma	ACACB RASSF2 ATXN7L1 ADGRV1 MICB MICA PBX2	1.23e-03	182	261	7	EFO_0001061
Disease	chronic kidney disease	GTPBP4 GIPC2 ATXN7L1 LARP4B DIAPH3 DSCAM MADD SLC34A1	1.23e-03	235	261	8	EFO_0003884
Disease	inflammatory bowel disease (implicated_via_orthology)	IL16 ANKZF1 PDZD2	1.36e-03	25	261	3	DOID:0050589 (implicated_via_orthology)
Disease	Alzheimer disease	ATXN7L1 ABCA7 FRMD4B ITIH1 PKHD1 MMP3 MAP4K4 CDCP1 SLC2A13 BCAM MYO15A PCDH7	1.39e-03	485	261	12	MONDO_0004975
Disease	hippocampal volume	AHI1-DT EPPK1 RYR3 PTPRD ACTL8 BRSK2 DIDO1 MADD DNAH11	1.40e-03	297	261	9	EFO_0005035
Disease	pulse pressure measurement	SETD6 ZNF318 SRCAP DYSF ITIH1 PTPRD COPS8 PKD1 ADAMTS15 SPINDOC DNMT3B NPAS2 CACNA1D FBLN5 DSCAM CARMIL1 MADD HIVEP3 KANSL1 SLC2A13 CDC25A PBX3 HYDIN PLCE1	1.48e-03	1392	261	24	EFO_0005763
Disease	macula measurement	DCHS2 MYO9A CDC42BPA CDCP1 KANSL1 SLC16A1 YLPM1	1.53e-03	189	261	7	EFO_0008375
Disease	recalcitrant atopic dermatitis	SCAPER NBAS	1.59e-03	7	261	2	EFO_1000651
Disease	Dengue Hemorrhagic Fever	MICB PLCE1	1.59e-03	7	261	2	EFO_0004227
Disease	atrioventricular septal defect (implicated_via_orthology)	NR1D2 DNAH11	1.59e-03	7	261	2	DOID:0050651 (implicated_via_orthology)
Disease	blood osmolality measurement	AHI1-DT KATNAL1 PKHD1 PARVA	1.74e-03	58	261	4	EFO_0007967
Disease	alkaline phosphatase measurement	ZHX3 GIPC2 ACACB ZNF318 NF1 CASKIN1 PKD1 HFM1 WHRN ZDHHC18 CARMIL1 ZFAND4 HIVEP3 LLGL1 KANSL1 BCAM LRBA ADAMTSL2 PLCE1	1.85e-03	1015	261	19	EFO_0004533
Disease	attention deficit hyperactivity disorder (implicated_via_orthology)	MEF2D NF1 CDH2	1.90e-03	28	261	3	DOID:1094 (implicated_via_orthology)
Disease	cortical surface area measurement	FILIP1 ZHX3 DCHS2 NFILZ ADGRV1 DYSF FRMD4B PKD1 PKHD1 MICA DIAPH3 MAP4K4 ITGA11 ZAN BRSK2 LAMA2 MARCHF7 NHSL1 KANSL1 PCDH7 PLCE1 PDZD2 DNAH11	2.05e-03	1345	261	23	EFO_0010736
Disease	platelet measurement	CFAP251 EPPK1 MICB SYT5 MICA GAPDHS VWF CARMIL1 ANKZF1	2.08e-03	315	261	9	EFO_0005036
Disease	glycylvaline measurement	GIPC2 DNAH11	2.11e-03	8	261	2	EFO_0021129
Disease	cerebellar ataxia (implicated_via_orthology)	VPS13C AARS2	2.11e-03	8	261	2	DOID:0050753 (implicated_via_orthology)
Disease	lean body mass	GIPC2 VPS13C ADGRV1 PTPRD DIAPH3 MTIF3 LAMA2 DIDO1 HEXIM2 PLCE1	2.15e-03	379	261	10	EFO_0004995
Disease	resting heart rate	ZHX3 EPPK1 FRMD4B MEF2D CACNA1D CDH2	2.17e-03	149	261	6	EFO_0004351
Disease	cortical thickness	ZHX3 KMT2B NFILZ ZNF318 ADGRV1 DYSF FRMD4B CDH20 PKD1 PKHD1 DIAPH3 COL12A1 LAMA2 LFNG NHSL1 KANSL1 YLPM1 PCDH7 PLCE1 PDZD2	2.27e-03	1113	261	20	EFO_0004840
Disease	Parkinson disease	LZTS3 ITIH1 DLG2 UXT MAP4K4 COL12A1 KANSL1 IGSF9B SLC2A13	2.37e-03	321	261	9	MONDO_0005180
Disease	blood urea nitrogen measurement	GIPC2 ZNF318 ADGRV1 LARP4B CDH20 PKHD1 CDC42BPA PPP1CA SLC34A1 LRBA PLCE1	2.46e-03	452	261	11	EFO_0004741
Disease	longitudinal alcohol consumption measurement	SPATA31C1 IGSF9B	2.69e-03	9	261	2	EFO_0007645
Disease	Agents acting on the renin-angiotensin system use measurement	ZNF318 SOX7 PKHD1 CACNA1D MIA3 FAM220A LFNG CDC25A PLCE1	3.14e-03	335	261	9	EFO_0009931
Disease	neuroimaging measurement	ZHX3 DCHS2 KMT2B DYSF FRMD4B NF1 PKD1 PKHD1 DLG2 CDC42BPA CARMIL1 BRSK2 LAMA2 NHSL1 KANSL1 PBX3 PCDH7 PLCE1 DNAH11	3.27e-03	1069	261	19	EFO_0004346
Disease	cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement	ACACB HFM1 MICA CARMIL1 MADD DNAH1 LLGL1 BCAM	3.33e-03	276	261	8	EFO_0004612, EFO_0020943
Disease	Nephroblastoma	DLG2 NBAS	3.35e-03	10	261	2	Orphanet_654
Disease	alpha wave measurement, electroencephalogram measurement	MSH2 DNAH1	3.35e-03	10	261	2	EFO_0004357, EFO_0006870
Disease	age at menarche, spine bone mineral density	SLC25A40 WHRN	3.35e-03	10	261	2	EFO_0004703, EFO_0007701
Disease	brain aneurysm	SOX7 PTPRD DSCAM PLCE1 PDZD2	3.37e-03	113	261	5	EFO_0003870
Disease	Malignant Glioma	MYLK TRIM29 NF1 ATP1B2	3.47e-03	70	261	4	C0555198
Disease	mixed gliomas	MYLK TRIM29 NF1 ATP1B2	3.47e-03	70	261	4	C0259783
Disease	chemokine (C-C motif) ligand 27 measurement	APTX IREB2 ITIH1 ITGA11	3.47e-03	70	261	4	EFO_0008082
Disease	colorectal adenocarcinoma (is_implicated_in)	IL16 KMT2B DNMT3B	3.63e-03	35	261	3	DOID:0050861 (is_implicated_in)
Disease	childhood trauma measurement, alcohol consumption measurement	PTPRD OSBPL5 MARCHF7 NLRP1	3.65e-03	71	261	4	EFO_0007878, EFO_0007979
Disease	creatinine measurement, glomerular filtration rate	GTPBP4 LARP4B CDH20 PRMT7 SLC34A1	3.91e-03	117	261	5	EFO_0004518, EFO_0005208
Disease	Primary ciliary dyskinesia	DNAH1 HYDIN DNAH11	3.94e-03	36	261	3	cv:C0008780
Disease	Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement	KCNB2 DNAH11	4.07e-03	11	261	2	EFO_0009923
Disease	autosomal recessive polycystic kidney disease (biomarker_via_orthology)	PKHD1 CDC25A	4.07e-03	11	261	2	DOID:0110861 (biomarker_via_orthology)
Disease	Bardet-Biedl syndrome (implicated_via_orthology)	SCAPER CEP131	4.07e-03	11	261	2	DOID:1935 (implicated_via_orthology)
Disease	response to radiation, prostate carcinoma, erectile dysfunction	ZC3H12B ACTL8 NFX1	4.26e-03	37	261	3	EFO_0001663, EFO_0004234, GO_0009314
Disease	body weight	GIPC2 SETD6 VPS13C MAP3K7CL ADGRV1 KCNB2 SPATA31C1 PKD1 DLG2 MICA PRMT7 MGA MTIF3 ST3GAL1 THSD7B SYT16 NBAS USF3 PHF3 PCDH7 PDZD2	4.31e-03	1261	261	21	EFO_0004338
Disease	non-small cell lung carcinoma	SAXO1 DSCAM NLRP1 THSD7B	4.45e-03	75	261	4	EFO_0003060
Disease	pursuit maintenance gain measurement	SPATA31C1 PTPRD CACNA1D CARMIL1 EPG5	4.83e-03	123	261	5	EFO_0008433
Disease	Dental enamel hypoplasia	PTPRD SCAPER	4.85e-03	12	261	2	EFO_1001304
Disease	kynurenine measurement	BRWD1 SLC34A1 DNAH11	4.94e-03	39	261	3	EFO_0008529
Disease	personality trait	PTPRD ST3GAL1 PLCE1	4.94e-03	39	261	3	EFO_0004365
Disease	Respiratory Depression	MECP2 FBLN5	5.70e-03	13	261	2	C0235063
Disease	Respiratory Failure	MECP2 FBLN5	5.70e-03	13	261	2	C1145670
Disease	X-24588 measurement	DNMBP ANKRD40	5.70e-03	13	261	2	EFO_0800898
Disease	advanced glycosylation end product-specific receptor, soluble measurement	KANSL1 PBX2	5.70e-03	13	261	2	EFO_0020131
Disease	Modic type vertebral endplate changes	PTPRD DLG2	5.70e-03	13	261	2	HP_0030775
Disease	Respiratory Insufficiency	MECP2 FBLN5	5.70e-03	13	261	2	C0035229
Disease	esophageal squamous cell carcinoma	ATP1B2 PLCE1	5.70e-03	13	261	2	EFO_0005922
Disease	Liver carcinoma	KMT2B MECP2 PPP4R3C MKI67 PKM MICA CNDP1 FOXM1 CDCA8 GMNN CEP131	5.80e-03	507	261	11	C2239176
Disease	Nonsyndromic Deafness	BDP1 ADGRV1 WHRN MYO15A	5.84e-03	81	261	4	C3711374
Disease	retinal nerve fibre layer thickness measurement	FRMD4B PTPRD NBAS	6.50e-03	43	261	3	EFO_0600004
Disease	autosomal dominant polycystic kidney disease (implicated_via_orthology)	PKD1 FLNC	6.61e-03	14	261	2	DOID:898 (implicated_via_orthology)
Disease	dystonia (is_implicated_in)	KMT2B VPS16	6.61e-03	14	261	2	DOID:543 (is_implicated_in)
Disease	atrial fibrillation (is_implicated_in)	MMP3 VWF	6.61e-03	14	261	2	DOID:0060224 (is_implicated_in)
Disease	bitter alcoholic beverage consumption measurement	NF1 PTPRD SCAPER DNAH2 IGSF9B	6.69e-03	133	261	5	EFO_0010092
Disease	Intellectual Disability	ACTL6A MECP2 DDX3X NF1 SCAPER CNDP1 BRSK2 GRIN2D KANSL1 CDH2	6.80e-03	447	261	10	C3714756
Disease	energy intake	BDP1 CDH20 PTPRD DLG2 PCDH7	6.90e-03	134	261	5	EFO_0003939
Disease	squamous cell lung carcinoma, family history of lung cancer	MFSD6L NF1 DLG2 NBAS	6.92e-03	85	261	4	EFO_0000708, EFO_0006953
Disease	left ventricular systolic function measurement	OBSCN ALPK3 FLNC	6.93e-03	44	261	3	EFO_0008206
Disease	age at menarche	KCNB2 SLC38A10 PTPRD DLG2 SPINDOC BRWD1 MTIF3 DSCAM DNAH2 THSD7B ECPAS MADD	7.00e-03	594	261	12	EFO_0004703
Disease	orofacial cleft, sex interaction measurement	NF1 OSBPL5 COL12A1 PLCE1	7.21e-03	86	261	4	EFO_0008343, MONDO_0000358

Protein segments in the cluster

Peptide	Gene	Start	Entry
VPAGRLIKEPTSLMD	ARSF	391	P54793
MEREKDNGIRPPSLE	EPB42	456	P16452
QVPMEDQIRLRPGSE	EPG5	2496	Q9HCE0
TVMRTAIAPGDKPQI	SLC4A3	1061	P48751
AINESQRPPDRSKMT	BDP1	171	A6H8Y1
GSDTPVMPKLFRETR	DNMT3B	81	Q9UBC3
PDGSRVELTPMQRVA	ACTL8	241	Q9H568
ETPRAKAQMPTIERL	CASP4	351	P49662
NERAMSLTIEPRPVK	CDCP1	351	Q9H5V8
KMSNGTRRIPVSPEQ	ACTR8	121	Q9H981
RVSRLPRHQKVPEMG	FAM220A	151	Q7Z4H9
LESKEKNTQGPRMPR	GTPBP4	496	Q9BZE4
RVPRENMEAISPLKN	ACTL6A	76	O96019
PEMKPRAGTEIRFSE	AAR2	196	Q9Y312
MLPSIAVSEPKGRNE	ADGRV1	151	Q8WXG9
KPLQRDSPGMVADRL	ACTL9	31	Q8TC94
SPTQGRKASMLEVPR	ALPK3	1416	Q96L96
RVTVRDGMPELLKLP	APTX	316	Q7Z2E3
AVMVLLAPRGRVPKD	DNAH11	3221	Q96DT5
SISERLEMKPGPQAQ	DNMBP	516	Q6XZF7
RLRSKGPATVEEMPS	GIPC2	226	Q8TF65
SQMISVREAKAIPRP	TENT2	406	Q6PIY7
KGEMPVQLTSRREIR	ANKRD40	76	Q6AI12
MLNSPGTRRPVKEAQ	AHI1-DT	1	P0C7V0
LPIGRDRVDMEVTLP	AGO4	96	Q9HCK5
KDVRQSLSPMSQRPV	DIAPH3	1086	Q9NSV4
KPEPVLATGSRMFLR	BMP1	826	P13497
GPQPLVRRKMTGSRD	CAMSAP1	631	Q5T5Y3
RSRDPEGSSRKQQPM	CECR2	576	Q9BXF3
MNRPIQVKPAASEGR	CELF6	116	Q96J87
LSEPGAARQPRIMEE	CIAO2A	21	Q9H5X1
GRAMATLDRKVPSPE	ATXN7L1	26	Q9ULK2
VEVLSVGKMTPPRVR	ADAMTS15	781	Q8TE58
PRISVREPMQTGIKA	ATP5F1A	181	P25705
GLDVTLRLKMPPQET	ABCA7	1171	Q8IZY2
TLIRPQDMKGASRSP	ADM	66	P35318
PSGLRQKLSRMEPVE	ANKRD34A	326	Q69YU3
QKLSRMEPVELDTPG	ANKRD34A	331	Q69YU3
RQPSGELEEKTDRMP	CFAP251	176	Q8TBY9
QSMREDSTGVPRPQI	CFAP206	581	Q8IYR0
QIPLEQKMTRTDPTR	GALNT16	271	Q8N428
TEGMPTVEPGLQRRL	RBM15B	806	Q8NDT2
GPSIRRQREFMPEEK	NFILZ	26	A0A5F9ZHS7
KPLQEDTPQLMRTRS	RASSF2	131	P50749
ERMQTRGKVPPERVE	RABGEF1	191	Q9UJ41
MAVLPGLSSPREKNE	RIMKLA	311	Q8IXN7
SGPKRPQDRVAVTDM	IREB2	446	P48200
MQGILDPRPTIIKAR	GPHN	646	Q9NQX3
MGPDRKEVPLSRGTQ	NIBAN3	1	Q86XR2
VEMTPVQRRIEPRSA	LLGL1	701	Q15334
KSGVVLRRTVPPMVN	MICA	196	Q29983
RESSVISTQGPKPMR	NPAS2	601	Q99743
MTSVAGRIPAPVEKS	ACACB	1046	O00763
GRIPAPVEKSVRRVM	ACACB	1051	O00763
RKNGTMPREVARDPQ	ASB8	221	Q9H765
IRRIVEQDTMPPKGV	DDX3X	361	O00571
MGLVANTKPIRPRIQ	SLC16A1	316	P53985
TRPISPKEIERMVGI	PBX3	191	P40426
TPEEMQARSLGRPIK	C19orf81	31	C9J6K1
GPLRRKAPQSLEVMA	CASKIN1	616	Q8WXD9
MRPEAIRQDPTRKGS	MAP4K4	886	O95819
EQSRTRPVAPKEMER	PBX2	196	P40425
QLKRIMEVVGTPSPE	MAPK11	231	Q15759
RRIPMEGQRDSAFPK	MYLK	401	Q15746
VQVLDARDPMGTRSP	GNL2	221	Q13823
GKPSLDRPIQAMERV	LFNG	226	Q8NES3
VPRVIMIVTDGRPQD	MATN2	161	O00339
MERAAARQQSIKPGP	MADD	1526	Q8WXG6
MAKLETLPVRADPGR	LZTS3	1	O60299
RTPMALPVDRKRSQE	NCKAP5L	1261	Q9HCH0
EGRESKVMPTLAPVV	MGA	3036	Q8IWI9
PTKPDATMVVRNRRL	ITIH1	851	P19827
LRSRMPEGTRPEAKE	IL31RA	671	Q8NI17
PGRFAVVMPRVQKLS	MYO15A	1111	Q9UKN7
REFLPQGPVAMRVAK	AUH	276	Q13825
AVQASMPEKEPSVLR	MMS19	631	Q96T76
QGLPLVEMPRKNSRD	FNDC9	176	Q8TBE3
EERSLPRKMPFVRGQ	LGALS9C	291	Q6DKI2
RLATPGLMIRPKTEN	ATP1B2	76	P14415
PPLKRMERASSRVGE	KIAA1109	3626	Q2LD37
EERSLPRKMPFVRGQ	LGALS9B	291	Q3B8N2
ERSLPRKMPFVRGQS	LGALS9	291	O00182
PSTKRRGQMLQPIIE	FAM13B	761	Q9NYF5
SDTLEVMRKPRCGVP	MMP3	81	P08254
AMGKRLSREQSTPPK	LARP4B	721	Q92615
KDTAKMGPPTARREQ	BRSK2	721	Q8IWQ3
TPAVGRLEVSMVKPT	CDCA8	171	Q53HL2
MPRAEPRATLGEQEK	CCDC28A	1	Q8IWP9
LMEKPDVVVGTPSRI	DDX56	131	Q9NY93
LPGRNRKESTSEQMP	ECPAS	541	Q5VYK3
KEDGNDEVMTPSRPR	NHSL1	1341	Q5SYE7
PAKRTAEVEMPGFRN	MFSD6L	141	Q8IWD5
QRLREMEKANPKTGP	MTIF3	141	Q9H2K0
LRFTVMARDRGQPPK	PCDH7	381	O60245
QGAPLLSTPKRERMV	KIF22	456	Q14807
RKTPGPKDRIVMEVT	PDZD2	716	O15018
RRKPSVMTPTEGLDT	NLRP1	986	Q9C000
AIPSAKVREQRMPRD	CSPP1	1071	Q1MSJ5
SPRPVSGMERERKVS	CSNK1D	356	P48730
EVRMPSGKTARPNIT	FLNC	1801	Q14315
ESQGPVLKMPSQRAR	IL16	951	Q14005
VKTRMQSLQPDPAAR	SLC25A28	96	Q96A46
TLTGVLEREMQARPP	NFX1	1071	Q12986
AVPMVERVTAPKAER	KANSL1	756	Q7Z3B3
KEPGARSSPLQAMRI	KLK11	21	Q9UBX7
LDGPRPNQKEMLSLR	LRBA	641	P50851
KEPVSLPGIMRRGES	LMO7	1496	Q8WWI1
TRPKARKQGVSPADM	ADAMTSL2	551	Q86TH1
LESMIKKPRPTRAEG	PKM	331	P14618
MVLKGKIRPDSSRPE	GLT8D2	116	Q9H1C3
RSNTPILVDGKDVMP	GPI	106	P06744
TGARTMRKIVIRPEP	LAMA2	2601	P24043
MKTPTVRGVLDLDRP	KMT2B	2326	Q9UMN6
GRNPKPVILVESIMR	LHFPL1	191	Q86WI0
KSGVAIRRTVPPMVN	MICB	196	Q29980
DTFNMDTRKPRVIPG	ITGA11	21	Q9UKX5
VTGTKRLRCMPAPEE	MKI67	3006	P46013
PLEMLQDQGKRSVPS	MLKL	41	Q8NB16
MVRLTRHTGRKQPPV	NBAS	1076	A2RRP1
VRMEGAEARGPPRIK	PTPRS	761	Q13332
AEARGPPRIKDVMLA	PTPRS	766	Q13332
TKRTQEGEAVMPPLE	PPP4R3C	706	Q6ZMV5
EMTVLVTDRGSPPRN	DCHS2	1261	Q6V1P9
NKDPNRITIRFPMEG	HFM1	836	A2PYH4
PESRLVPKLRQAGAM	SLC34A1	86	Q06495
PVDPVVKARMESSVI	OBSCN	516	Q5VST9
TRDGRRESVPPSIIM	NDUFA7	56	O95182
QALLRSGDKVRMDPP	CTSA	316	P10619
IRRIMRPTDVPDQGL	PPP1CA	186	P62136
QPTMEPVGRKRSRKA	FAM9A	41	Q8IZU1
QIRPIVMSQKDGDRP	OPN3	346	Q9H1Y3
KTLERRPQGGRSMPT	FRMD4B	651	Q9Y2L6
QNGSKMTIEPPRGVR	DNAH1	3776	Q9P2D7
MTIEPPRGVRANLLK	DNAH1	3781	Q9P2D7
IAVPRKDRMSPVTIA	IL36A	31	Q9UHA7
KEPPGAQLRTSALME	IGSF10	691	Q6WRI0
DVPRNMPGTFTTKRK	HYDIN	3756	Q4G0P3
PEEVRKSALTLVMGP	HEATR5B	846	Q9P2D3
MAEKAPPGLNRKTSR	KCNB2	1	Q92953
AMVTFRTGRRPKPEI	BOC	561	Q9BWV1
RTGRRPKPEIMASKE	BOC	566	Q9BWV1
TRPKEVRLGPTVNDM	COL12A1	1516	Q99715
SPERKLLQGPMDISE	ANKZF1	56	Q9H8Y5
TSPEKNERVRQMRPV	PRMT7	351	Q9NVM4
TGRPMEPESEFIIKI	CDH20	141	Q9HBT6
EAESIRKRPMLGPSE	CRACD	741	Q6ZU35
TPEAGRKEKPMLQSR	CRACD	1056	Q6ZU35
PMRPGILVQRQSKEV	C2orf74	81	A8MZ97
MAEEEGPPVELRQRK	DPY19L4	1	Q7Z388
MVEARQDVPKPVLTS	DIDO1	991	Q9BTC0
RPQRMPVSTKPVEDD	ABCA2	2016	Q9BZC7
TLRKSPFVPQMGDEV	BRWD1	951	Q9NSI6
MESKPSRIPRRISVQ	MARCHF7	1	Q9H992
MDPAVIAGVLSRKSP	LYG1	81	Q8N1E2
NPELRRNMTIKTELP	FOXM1	346	Q08050
KTQRPEEMPISNLGR	HCAR1	306	Q9BXC0
LPRSGEQERKNPMAL	HEPACAM	296	Q14CZ8
DSTTRMVLPRKPVAG	COPS8	156	Q99627
ILMTEEPSSPKGAVR	CARMIL1	1086	Q5VZK9
IDPKTGVIRTALPNM	CDH12	211	P55289
RPVIILGPMKDRIND	DLG2	681	Q15700
SATLVMTRPIKGPRE	FBLN5	401	Q9UBX5
MTRPIKGPREIQLDL	FBLN5	406	Q9UBX5
RIVEQDTMPPKGVRH	DDX3Y	361	O15523
PPKMVSVARELTVGI	GAPDHS	66	O14556
SVPPLVEVMRGKSVI	BCAM	36	P50895
GRTELPENLKSMFRP	DNAH2	1911	Q9P225
GRPIRSRSTAVMPKV	SCAPER	271	Q9BY12
KPDGTRVLPNVMSRL	SALL4	316	Q9UJQ4
TGDPRMKPKQVSRDL	SLC38A10	921	Q9HBR0
RETRVPGMRQPAQEL	CEP131	366	Q9UPN4
RRMEPLEKTGPAAVF	DYSF	1096	O75923
EIPRPLKRRGSMEQA	PPP1R13L	516	Q8WUF5
MPEKPTTTVRLFDRG	MSH2	26	P43246
AGPRPRRISELNMKE	CACNA1D	841	Q01668
VEPDAIKPVGIRRMD	CDH2	796	P19022
PEPEAEGSAVKRMRL	MEF2D	501	Q14814
QTVSAKGPPEKRMRL	MED6	231	O75586
PLDSKENLENPMRRI	CDC25A	91	P30304
EKLMPVSAQTPKGRR	MPHOSPH8	376	Q99549
QDSIRRMGLAPKDPA	PIDD1	881	Q9HB75
EPVEVMVFPGLRLSR	PKD1	571	P98161
GRSIQASRKEKMQPP	SLC51B	56	Q86UW2
PTIDMGPQLKVVERT	PTPRD	126	P23468
KQLRPGMDLSRVVLP	OSBPL5	376	Q9H0X9
GERKDIVSSSMPRPN	MECP2	456	P51608
LTERVVAALPEGMRP	MIA2	626	Q96PC5
AESMQPQRGERIPKN	NR1D2	276	Q14995
VPRRTLKMIQPSASG	GMNN	21	O75496
MISTARVPADKPVRI	MAP3K7CL	1	P57077
PPAGAMSTKQEARRD	NRIP2	46	Q9BQI9
MNARKTPLPEIGRRV	NRK	56	Q7Z2Y5
LSSLMGERRRKQPEP	SLC2A13	16	Q96QE2
VRGPASIRPMKNITA	DSCAM	501	O60469
VRPKVRTQAQIMPGA	GPRASP1	36	Q5JY77
PRGNIKVLMATNRPD	PSMC2	311	P35998
RVPMSSVDLGRPVQA	SYT5	211	O00445
EMPAAKRLRLDTGPQ	GTF2F1	416	P35269
SPRRLRNDPVVMVSK	TAS2R50	251	P59544
PNREVRPLRKEMAGV	KATNAL1	116	Q9BW62
PGDKGSESRIRRPMN	SOX7	36	Q9BT81
MRAVDVRIESNPVPG	SUSD5	111	O60279
RKPTVSIMEPGETRR	TRIM29	136	Q14134
TEKMRPLIVGRSASP	TIGD6	221	Q17RP2
KLPVRTETAMPRLGA	GINS3	31	Q9BRX5
KGPIPMEGLTTSRRD	SAXO1	61	Q8IYX7
ATGKEMPQDLRSPAR	SGTA	66	O43765
SMEKPPSLGDQETRR	SPAG7	11	O75391
PPLAEDSIQVVKSMR	STRIP2	301	Q9ULQ0
PEGEMKVTLVLEPRS	SYT16	461	Q17RD7
GARTPPLSRRKAVDM	TSC22D4	226	Q9Y3Q8
PPESIKAVARRNEMI	SAMD7	76	Q7Z3H4
MDPETRGQEIIKVTP	SLC25A40	1	Q8TBP6
TGGREPNTMVEKERP	MIA3	801	Q5JRA6
LRPSVNGRRMVDVPV	FILIP1	786	Q7Z7B0
VTKRSPEAPQPVIAM	HCLS1	271	P14317
NGEKIMTSDSRPIVP	NCOA7	336	Q8NI08
VTLPFSVPIMGRRTK	NKPD1	301	Q17RQ9
LTTVPEMKPQGLRIE	NKTR	1251	P30414
GRVMEPPSTVEIRQD	PLCE1	376	Q9P212
RVREEMFAKGQPVAP	HEXIM2	126	Q96MH2
TKLLAQARVMVPGPR	EPPK1	1186	P58107
GKRAPTPIREKEVTM	FGD1	721	P98174
MATQAKRPRVAGPVD	SETD6	1	Q8TBK2
FRVVPGNVDPMLEKR	ST3GAL1	121	Q11201
RPEPMLRVTQQEKTP	SPINDOC	36	Q9BUA3
LRREIESMKARQPPG	WHRN	496	Q9P202
NVKPRLDMVEPSRAA	PKHD1	1016	P08F94
VILRVKEGMPPTISA	PKHD1	2711	P08F94
KQTGRSPQKEDRIPM	FAM13C	541	Q8NE31
PRRPTMSTVVELNVG	KCTD14	26	Q9BQ13
TLLGEPPMASLRKQV	SPATA31C1	711	P0DKV0
RMLQPVPKQEGRTVV	SRCAP	996	Q6ZRS2
RTMVDPNSRSDPKLQ	PARVA	81	Q9NVD7
LMPEEEFLRRNKGPV	SF3A1	691	Q15459
LRDPEMRNKLISNPT	CDC42BPA	1561	Q5VT25
MGLAVDPNRAVPLRK	NOP16	56	Q9Y3C1
RAVRFSMEILKAPPG	AARS2	356	Q5JTZ9
GRRVMDSPERPVVNA	SPICE1	471	Q8N0Z3
ADEVQRSMGSPRPKT	ADD2	446	P35612
MAEEQGRERDSVPKP	ALG2	1	Q9H553
EPDMIRDGSTIPIAK	CNDP1	441	Q96KN2
QEMGPKLQARETPSL	CNGB1	201	Q14028
EAREFKPPQMRGSTR	C10orf67	56	Q8IYJ2
PRMKGRQPLTVFVEL	PRAMEF4	141	O60810
LLAVEGPAAKRTMRP	PDCD11	991	Q14690
ERQQEIAKMGTPVPR	SF3B2	191	Q13435
GPAEVRVSNVRPKMK	USP6NL	521	Q92738
DVMPSVKGAQERLPT	UBFD1	201	O14562
MVVRRDPGNTEPVKA	TSR1	596	Q2NL82
DIPVEGEITIPMRSR	YIPF6	31	Q96EC8
MATPPKRRAVEATGE	UXT	1	Q9UBK9
MVTGNPASDEIKRLP	VWF	1606	P04275
MRPDDINPRTGLVVA	TMEM215	1	Q68D42
GQPAAKRMLSPTREK	IGSF9B	801	Q9UPX0
NTKTPRERSILGMPD	RYR3	3081	Q15413
IRVTKILGDMPDPTQ	RYR3	4226	Q15413
PGTERNPEMELEKVR	TMEM247	96	A6NEH6
ARGEAPEVALKMPRL	PRX	346	Q9BXM0
DRRRQPLPTAAGEEM	TRIL	426	Q7L0X0
DLKLRRMPEVPGLQS	VPS16	161	Q9H269
QRPERVKPFMTGAAE	TPT1	106	P13693
EAGRLVPSSSRKPRM	HIVEP3	1671	Q5T1R4
LPPDTLEMRVRDGSK	RPP25L	21	Q8N5L8
SGITTPPKMRRVAET	NF1	2561	P21359
LRKMGQPVLPRRSSE	PHF3	856	Q92576
KQSGSPEEMVLLPRQ	VPS13C	2991	Q709C8
TEKRGSIVRFMPDSP	USF3	2031	Q68DE3
PVTVKMQLRRPSDQE	REL	256	Q04864
KEARVDIPPLMRGLT	TBCK	461	Q8TEA7
IRRIMRPTDVPDQGL	PPP1CC	186	P36873
APKRQSDPSIRSVAM	ZC3H12B	431	Q5HYM0
PQIREGMKRVEPQTE	POGLUT2	471	Q6UW63
APSQPITAVKDMPVR	YLPM1	726	P49750
GRFDMQVTVPRPDVK	YME1L1	496	Q96TA2
MKPLDSPGRRKRDTN	TRIP11	1886	Q15643
GQVMTKRCPDSTRPE	THSD7B	711	Q9C0I4
NTRRVPTDDPLRKMA	ZFAND4	106	Q86XD8
VPRPVAVTDGAMSKV	VSIG10L2	76	P0DP72
SIMAQTGLPRPEVVR	ZHX3	796	Q9H4I2
VPKPLGSSESEVMRQ	ZNF318	551	Q5VUA4
ILQTPKIMRDPDTGN	SF3B4	126	Q15427
PPRTREVLINGQMVK	ZDHHC18	176	Q9NUE0
KQMDPLNRPKTEGRS	ZFYVE9	211	O95405
LLVEGRNKMDPPRSS	ZAN	2371	Q9Y493
PEGTVMSGRRKTVDP	MYO9A	2516	B2RTY4
RIRVVEKAGPPINVM	MYBPC2	926	Q14324
PRTMQESPLGLQVKE	MZF1	171	P28698
PTPITPEMERVKRNQ	NEB	6256	P20929
ATATPVTPEMQRVKR	NEB	6316	P20929
PVENPRGTTSKIMVL	GRIN2D	646	O15399